Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
22,700 | 2023-03-23 00:00:00 UTC | 2 High-Yield Dividend Stocks You Won't Regret Buying Right Now | ABBV | https://www.nasdaq.com/articles/2-high-yield-dividend-stocks-you-wont-regret-buying-right-now | null | null | High-yield dividend stocks can be great for managing the ongoing reset in global equity markets. That said, these highly coveted income plays can also be fraught with risk, so it's important for investors to understand the threats and opportunities of the business behind the yield.
Which high-yield dividend stocks are ... | AbbVie's success as a top investing vehicle can be attributed to three key factors: The company's flagship immunology drug Humira, which has racked up over $135 billion in U.S. sales since its launch two decades ago, has long been one of the best-selling medications in the world. What's more, AbbVie's next wave of immu... | AbbVie AbbVie (NYSE: ABBV) is an Illinois-based drugmaker with significant commercial footprints in the areas of immunology, hematology, and medical aesthetics. AbbVie's success as a top investing vehicle can be attributed to three key factors: The company's flagship immunology drug Humira, which has racked up over $13... | AbbVie's deep commitment to paying a top-notch dividend yield, which presently stands at 3.85% on annualized basis, has attracted a favorable mix of institutional and income-seeking retail investors (i.e., investors that rarely sell shares due to the regular income provided by a stock). AbbVie AbbVie (NYSE: ABBV) is an... | AbbVie AbbVie (NYSE: ABBV) is an Illinois-based drugmaker with significant commercial footprints in the areas of immunology, hematology, and medical aesthetics. AbbVie's success as a top investing vehicle can be attributed to three key factors: The company's flagship immunology drug Humira, which has racked up over $13... |
22,701 | 2023-03-23 00:00:00 UTC | AbbVie: Phase 3 Induction Study With Risankizumab Meets Endpoints | ABBV | https://www.nasdaq.com/articles/abbvie%3A-phase-3-induction-study-with-risankizumab-meets-endpoints | null | null | (RTTNews) - AbbVie (ABBV) reported positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab met the primary endpoint of clinical remission at week 12, as well as all secondary endpoints in adult patients with moderately to severely active ulcerative colitis. In the study, 20.3% of patient... | (RTTNews) - AbbVie (ABBV) reported positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab met the primary endpoint of clinical remission at week 12, as well as all secondary endpoints in adult patients with moderately to severely active ulcerative colitis. Risankizumab is part of a coll... | (RTTNews) - AbbVie (ABBV) reported positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab met the primary endpoint of clinical remission at week 12, as well as all secondary endpoints in adult patients with moderately to severely active ulcerative colitis. Risankizumab is part of a coll... | (RTTNews) - AbbVie (ABBV) reported positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab met the primary endpoint of clinical remission at week 12, as well as all secondary endpoints in adult patients with moderately to severely active ulcerative colitis. Risankizumab is part of a coll... | (RTTNews) - AbbVie (ABBV) reported positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab met the primary endpoint of clinical remission at week 12, as well as all secondary endpoints in adult patients with moderately to severely active ulcerative colitis. Risankizumab is part of a coll... |
22,702 | 2023-03-23 00:00:00 UTC | Use These 3 Strategies to Make $1,000 in Passive Income Per Year | ABBV | https://www.nasdaq.com/articles/use-these-3-strategies-to-make-%241000-in-passive-income-per-year | null | null | Passive income is a holy grail for many investors, but it's a lot easier to want it than it is to make enough of it from your holdings. Buying shares of any old dividend stock simply won't do; you need a strategy that's right for your goals and your means.
So, let's explore three strategies that can help you invest for... | Take pharmaceuticals company AbbVie (NYSE: ABBV) as an example. But over the past 10 years, AbbVie's annual dividend per share increased by an average of 15.4% per year. Of course, that assumes AbbVie's dividend yield remains roughly the same in the period, which it might not, and also that its dividend won't get cut, ... | Take pharmaceuticals company AbbVie (NYSE: ABBV) as an example. But over the past 10 years, AbbVie's annual dividend per share increased by an average of 15.4% per year. Of course, that assumes AbbVie's dividend yield remains roughly the same in the period, which it might not, and also that its dividend won't get cut, ... | Take pharmaceuticals company AbbVie (NYSE: ABBV) as an example. But over the past 10 years, AbbVie's annual dividend per share increased by an average of 15.4% per year. Of course, that assumes AbbVie's dividend yield remains roughly the same in the period, which it might not, and also that its dividend won't get cut, ... | Take pharmaceuticals company AbbVie (NYSE: ABBV) as an example. But over the past 10 years, AbbVie's annual dividend per share increased by an average of 15.4% per year. Of course, that assumes AbbVie's dividend yield remains roughly the same in the period, which it might not, and also that its dividend won't get cut, ... |
22,703 | 2023-03-23 00:00:00 UTC | 2 Reasons to Buy AbbVie, and 1 Reason to Sell | ABBV | https://www.nasdaq.com/articles/2-reasons-to-buy-abbvie-and-1-reason-to-sell | null | null | AbbVie (NYSE: ABBV) wowed investors last year when it outperformed the S&P 500 index. Shares of the pharmaceutical company climbed 19%, while the benchmark fell by as much.
Since the start of the year, though, AbbVie shares have lost momentum. Why? The company's blockbuster immunology drug, Humira, is facing competitio... | At the same time, AbbVie has continued increasing its dividend, making it a solid choice for investors seeking passive income. AbbVie (NYSE: ABBV) wowed investors last year when it outperformed the S&P 500 index. Since the start of the year, though, AbbVie shares have lost momentum. | Reason to buy: The financial picture AbbVie completed its purchase of Allergan back in 2020. AbbVie (NYSE: ABBV) wowed investors last year when it outperformed the S&P 500 index. Since the start of the year, though, AbbVie shares have lost momentum. | Let's look at two reasons to buy AbbVie right now -- and one reason to sell. Reason to buy: Two new growth drivers AbbVie has been preparing for Humira's loss of exclusivity by developing two other immunology drugs that may take over where Humira's leaving off. Yes, AbbVie stock may not soar in the near term, but the c... | AbbVie (NYSE: ABBV) wowed investors last year when it outperformed the S&P 500 index. Since the start of the year, though, AbbVie shares have lost momentum. At the same time, AbbVie's full portfolio of other blockbusters and a pipeline of promising candidates give us reason to be positive about the company. |
22,704 | 2023-03-22 00:00:00 UTC | US FDA declines to approve AbbVie's Parkinson's disease therapy | ABBV | https://www.nasdaq.com/articles/us-fda-declines-to-approve-abbvies-parkinsons-disease-therapy | null | null | Adds background
March 22 (Reuters) - AbbVie Inc ABBV.N said on Wednesday the U.S. Food and Drug Administration had declined to approve its Parkinson's disease therapy for adults.
The U.S. health regulator has sought additional information about the delivery pump, which is part of the marketing application, the drugmake... | Adds background March 22 (Reuters) - AbbVie Inc ABBV.N said on Wednesday the U.S. Food and Drug Administration had declined to approve its Parkinson's disease therapy for adults. Abbvie said it plans to resubmit the marketing application as soon as possible. The U.S. health regulator has sought additional information a... | Adds background March 22 (Reuters) - AbbVie Inc ABBV.N said on Wednesday the U.S. Food and Drug Administration had declined to approve its Parkinson's disease therapy for adults. Abbvie said it plans to resubmit the marketing application as soon as possible. The U.S. health regulator has sought additional information a... | Adds background March 22 (Reuters) - AbbVie Inc ABBV.N said on Wednesday the U.S. Food and Drug Administration had declined to approve its Parkinson's disease therapy for adults. Abbvie said it plans to resubmit the marketing application as soon as possible. The U.S. health regulator has sought additional information a... | Adds background March 22 (Reuters) - AbbVie Inc ABBV.N said on Wednesday the U.S. Food and Drug Administration had declined to approve its Parkinson's disease therapy for adults. Abbvie said it plans to resubmit the marketing application as soon as possible. The U.S. health regulator has sought additional information a... |
22,705 | 2023-03-22 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-4 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,706 | 2023-03-22 00:00:00 UTC | AbbVie: FDA Requests Additional Information Related To NDA Review Of ABBV-951 | ABBV | https://www.nasdaq.com/articles/abbvie%3A-fda-requests-additional-information-related-to-nda-review-of-abbv-951 | null | null | (RTTNews) - AbbVie (ABBV) announced it received a Complete Response Letter from the FDA for the New Drug Application for ABBV-951 for the treatment of motor fluctuations in adults with advanced Parkinson's disease. The FDA requested additional information about the device as part of the NDA review. The company plans to... | (RTTNews) - AbbVie (ABBV) announced it received a Complete Response Letter from the FDA for the New Drug Application for ABBV-951 for the treatment of motor fluctuations in adults with advanced Parkinson's disease. ABBV-951 or foscarbidopa/foslevodopa is a solution of carbidopa and levodopa prodrugs for continuous subc... | (RTTNews) - AbbVie (ABBV) announced it received a Complete Response Letter from the FDA for the New Drug Application for ABBV-951 for the treatment of motor fluctuations in adults with advanced Parkinson's disease. ABBV-951 or foscarbidopa/foslevodopa is a solution of carbidopa and levodopa prodrugs for continuous subc... | (RTTNews) - AbbVie (ABBV) announced it received a Complete Response Letter from the FDA for the New Drug Application for ABBV-951 for the treatment of motor fluctuations in adults with advanced Parkinson's disease. ABBV-951 or foscarbidopa/foslevodopa is a solution of carbidopa and levodopa prodrugs for continuous subc... | (RTTNews) - AbbVie (ABBV) announced it received a Complete Response Letter from the FDA for the New Drug Application for ABBV-951 for the treatment of motor fluctuations in adults with advanced Parkinson's disease. ABBV-951 or foscarbidopa/foslevodopa is a solution of carbidopa and levodopa prodrugs for continuous subc... |
22,707 | 2023-03-22 00:00:00 UTC | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-a-trending-stock%3A-facts-to-know-before-betting-on-it-5 | null | null | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this drugmaker have returned +3.1%, compared to the Zacks S&P 500 composite's +0.3% change. Dur... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry... | Last Reported Results and Surprise History AbbVie reported revenues of $15.12 billion in the last reported quarter, representing a year-over-year change of +1.6%. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie ... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which ... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which ... |
22,708 | 2023-03-22 00:00:00 UTC | Here's What is Driving Amgen (AMGN) Stock's Outperformance | ABBV | https://www.nasdaq.com/articles/heres-what-is-driving-amgen-amgn-stocks-outperformance | null | null | Amgen AMGN is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology and neuroscience markets.
Thousand Oaks, CA-based Amgen also has a promising pipeline of cancer drugs. It has one of the stro... | It markets Kanjinti (a biosimilar of Roche’s Herceptin) and Mvasi (a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita was launched in January 2023. Click to ... | Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Horizon Therapeutics Public Limited Company (HZNP) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. It markets Kanjint... | Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Horizon Therapeutics Public Limited Company (HZNP) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. It markets Kanjint... | It markets Kanjinti (a biosimilar of Roche’s Herceptin) and Mvasi (a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita was launched in January 2023. Click to ... |
22,709 | 2023-03-21 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-72 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | Get the latest Zacks research report on ABBV — FREE Get the latest Zacks research report on PII — FREE Dividend Growth Stocks: 25 Aristocrats » Also see: Top Stocks Held By Warren Buffett Institutional Holders of PHYL Funds Holding BLOX The views and opinions expressed herein are the views and opinions of the aut... | Nordson Corp. (Symbol: NDSN) $208.16 $256.00 22.98% RenaissanceRe Holdings Ltd. (Symbol: RNR) $192.47 $228.25 18.59% National Retail Properties Inc (Symbol: NNN) $42.66 $50.44 18.25% AbbVie Inc (Symbol: ABBV) $156.12 $165.73 6.16% Polaris Inc (Symbol: PII) $107.51 $113.90 5.94% The average 12-month analyst targets are ... | Nordson Corp. (Symbol: NDSN) $208.16 $256.00 22.98% RenaissanceRe Holdings Ltd. (Symbol: RNR) $192.47 $228.25 18.59% National Retail Properties Inc (Symbol: NNN) $42.66 $50.44 18.25% AbbVie Inc (Symbol: ABBV) $156.12 $165.73 6.16% Polaris Inc (Symbol: PII) $107.51 $113.90 5.94% The average 12-month analyst targets are ... | Nordson Corp. (Symbol: NDSN) $208.16 $256.00 22.98% RenaissanceRe Holdings Ltd. (Symbol: RNR) $192.47 $228.25 18.59% National Retail Properties Inc (Symbol: NNN) $42.66 $50.44 18.25% AbbVie Inc (Symbol: ABBV) $156.12 $165.73 6.16% Polaris Inc (Symbol: PII) $107.51 $113.90 5.94% The average 12-month analyst targets are ... |
22,710 | 2023-03-20 00:00:00 UTC | Should You Buy The Botox Maker Over Johnson & Johnson Stock? | ABBV | https://www.nasdaq.com/articles/should-you-buy-the-botox-maker-over-johnson-johnson-stock | null | null | We believe that AbbVie stock (NYSE: ABBV) is currently a better pick than its industry peer, Johnson & Johnson stock (NYSE: JNJ), given its better growth prospects. Although AbbVie is trading at 4.8x trailing revenues compared to 4.2x for J&J, this gap in valuation looks justified, given the former’s superior revenue g... | That said, AbbVie is prepared to combat this biosimilar impact with its Allergan acquisition in 2020, giving it access to Botox, a multi-billion dollar product. We believe that AbbVie stock (NYSE: ABBV) is currently a better pick than its industry peer, Johnson & Johnson stock (NYSE: JNJ), given its better growth prosp... | We believe that AbbVie stock (NYSE: ABBV) is currently a better pick than its industry peer, Johnson & Johnson stock (NYSE: JNJ), given its better growth prospects. Our Johnson & Johnson Operating Income Comparison and AbbVie Operating Income Comparison dashboards have more details. Total [2] JNJ Return -1% -14% 32% AB... | We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Johnson & Johnson vs. AbbVie: Which Stock Is A Better Bet? Even if we look at a longer time frame, AbbVie fares better, with its sales rising at an average annual growth rate of 21% to $58 bi... | We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Johnson & Johnson vs. AbbVie: Which Stock Is A Better Bet? While AbbVie’s sales are expected to fall in 2023, in one of its recent SEC filings, the company stated that it will absorb the loss... |
22,711 | 2023-03-20 00:00:00 UTC | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-outpaces-stock-market-gains%3A-what-you-should-know-2 | null | null | In the latest trading session, AbbVie (ABBV) closed at $156.12, marking a +1.23% move from the previous day. This move outpaced the S&P 500's daily gain of 0.89%. Meanwhile, the Dow gained 1.2%, and the Nasdaq, a tech-heavy index, lost 0.68%.
Heading into today, shares of the drugmaker had gained 1.92% over the past mo... | In the latest trading session, AbbVie (ABBV) closed at $156.12, marking a +1.23% move from the previous day. AbbVie will be looking to display strength as it nears its next earnings release. On that day, AbbVie is projected to report earnings of $2.49 per share, which would represent a year-over-year decline of 21.2%. | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. In the latest trading session, AbbVie (ABBV) closed at $156.12, marking a +1.23% move from the previous day. AbbVie will be looking to display strength as it nears its next earnings release. | In the latest trading session, AbbVie (ABBV) closed at $156.12, marking a +1.23% move from the previous day. AbbVie will be looking to display strength as it nears its next earnings release. On that day, AbbVie is projected to report earnings of $2.49 per share, which would represent a year-over-year decline of 21.2%. | On that day, AbbVie is projected to report earnings of $2.49 per share, which would represent a year-over-year decline of 21.2%. In the latest trading session, AbbVie (ABBV) closed at $156.12, marking a +1.23% move from the previous day. AbbVie will be looking to display strength as it nears its next earnings release. |
22,712 | 2023-03-20 00:00:00 UTC | Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)? | ABBV | https://www.nasdaq.com/articles/should-you-invest-in-the-invesco-dynamic-pharmaceuticals-etf-pjp-6 | null | null | The Invesco Dynamic Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.
While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among instit... | Looking at individual holdings, Pfizer Inc (PFE) accounts for about 6.84% of total assets, followed by Merck & Co Inc (MRK) and Abbvie Inc (ABBV). Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free S... | Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharmaceut... | Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharmaceut... | Looking at individual holdings, Pfizer Inc (PFE) accounts for about 6.84% of total assets, followed by Merck & Co Inc (MRK) and Abbvie Inc (ABBV). Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free S... |
22,713 | 2023-03-20 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-3 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,714 | 2023-03-20 00:00:00 UTC | Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar-5 | null | null | Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the First Trust Morningstar Dividend Leaders ETF (FDL) is a passively managed exchange traded fund launched on 03/09/2006.
The fund is sponsored by First Trust Advisors. It has amassed assets over $4.90 billion, making it one of ... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 10.47% of total assets, followed by Verizon Communications Inc. (VZ) and Abbvie Inc. (ABBV). Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock ... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 10.47% of total assets, followed by Verizon Communications Inc. (VZ) and Abbvie Inc. (ABBV). Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock ... | Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Verizon Communications Inc. (VZ) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports i... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 10.47% of total assets, followed by Verizon Communications Inc. (VZ) and Abbvie Inc. (ABBV). Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock ... |
22,715 | 2023-03-17 00:00:00 UTC | After Hours Most Active for Mar 17, 2023 : LUMN, F, HBI, ABBV, IBM, PEB, INTC, GOOG, AAPL, HBAN, AMZN, VSAT | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-for-mar-17-2023-%3A-lumn-f-hbi-abbv-ibm-peb-intc-goog-aapl-hban-amzn | null | null | The NASDAQ 100 After Hours Indicator is down -5.75 to 12,514.13. The total After hours volume is currently 510,996,400 shares traded.
The following are the most active stocks for the after hours session:
Lumen Technologies, Inc. (LUMN) is -0.02 at $2.46, with 101,594,315 shares traded. LUMN's current last sale is 41%... | AbbVie Inc. (ABBV) is +0.28 at $154.50, with 15,926,629 shares traded. ABBV's current last sale is 94.79% of the target price of $163. International Business Machines Corporation (IBM) is +0.0123 at $123.70, with 14,078,168 shares traded. | AbbVie Inc. (ABBV) is +0.28 at $154.50, with 15,926,629 shares traded. ABBV's current last sale is 94.79% of the target price of $163. The total After hours volume is currently 510,996,400 shares traded. | AbbVie Inc. (ABBV) is +0.28 at $154.50, with 15,926,629 shares traded. ABBV's current last sale is 94.79% of the target price of $163. The total After hours volume is currently 510,996,400 shares traded. | AbbVie Inc. (ABBV) is +0.28 at $154.50, with 15,926,629 shares traded. ABBV's current last sale is 94.79% of the target price of $163. LUMN's current last sale is 41% of the target price of $6. |
22,716 | 2023-03-17 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-2 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,717 | 2023-03-16 00:00:00 UTC | 2 Growth Stocks to Buy Before the Bull Market Arrives | ABBV | https://www.nasdaq.com/articles/2-growth-stocks-to-buy-before-the-bull-market-arrives | null | null | Timing the market is a risky strategy. If you wait too long, you can miss the rally when it inevitably comes. Investors react quickly to news, and so if you've found a good stock at a decent valuation, you shouldn't wait to buy it. Provided you're willing to buy and hold for years, now may be a good time to buy stocks ... | A couple of stocks that look particularly good right now include AbbVie (NYSE: ABBV) and Nvidia (NASDAQ: NVDA). AbbVie Drugmaker AbbVie makes for both a solid growth stock and an income investment. Investors have probably been discounting AbbVie as a result of the loss in patent protection for its top-selling drug, Hum... | But the company's outlook and growth opportunities remain strong; AbbVie has more than 50 programs in its pipeline that are in mid- and late-stage trials that could help the company develop the next blockbuster drug. A couple of stocks that look particularly good right now include AbbVie (NYSE: ABBV) and Nvidia (NASDAQ... | When the bull market finally arrives, AbbVie is a stock I would expect should be overdue for a big rally as investors are overlooking a solid business. A couple of stocks that look particularly good right now include AbbVie (NYSE: ABBV) and Nvidia (NASDAQ: NVDA). AbbVie Drugmaker AbbVie makes for both a solid growth st... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! A couple of stocks that look particularly good right now include AbbVie (NYSE: ABBV) and Nvidia (NASDAQ: NVDA). AbbVie Drugmaker AbbVie makes for both a solid growth stock and an income invest... |
22,718 | 2023-03-15 00:00:00 UTC | U.S. issues initial Medicare drug price negotiation guidance | ABBV | https://www.nasdaq.com/articles/u.s.-issues-initial-medicare-drug-price-negotiation-guidance | null | null | By Ahmed Aboulenein and Michael Erman
WASHINGTON, March 15 (Reuters) - The U.S. government will select the Medicare program's 10 costliest prescription medicines based on gross spending for negotiating price cuts that will go into effect in 2026, the U.S. Centers for Medicare and Medicaid Services (CMS) said on Wednesd... | Big-selling drugs made by Bristol Myers Squibb BMY.N, Pfizer PFE.N, and AbbVie ABBV.N are likely to be among the medicines subject to the first round of price negotiations, according to analyses by academics and Wall Street analysts shared with Reuters. Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price nego... | Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation (Reporting by Ahmed Aboulenein in Washington and Michael Erman in New York; Editing by Leslie Adler and Bill Berkrot) ((ahmed.aboulenein@tr.com; +1 202-519-3051;)) The views and opinions expressed herein are the views and opinions of the author a... | Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation (Reporting by Ahmed Aboulenein in Washington and Michael Erman in New York; Editing by Leslie Adler and Bill Berkrot) ((ahmed.aboulenein@tr.com; +1 202-519-3051;)) The views and opinions expressed herein are the views and opinions of the author a... | Big-selling drugs made by Bristol Myers Squibb BMY.N, Pfizer PFE.N, and AbbVie ABBV.N are likely to be among the medicines subject to the first round of price negotiations, according to analyses by academics and Wall Street analysts shared with Reuters. Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price nego... |
22,719 | 2023-03-15 00:00:00 UTC | US to impose inflation fines on first set of drugs, lowering costs | ABBV | https://www.nasdaq.com/articles/us-to-impose-inflation-fines-on-first-set-of-drugs-lowering-costs-0 | null | null | By Ahmed Aboulenein
WASHINGTON, March 15 (Reuters) - The U.S. government said on Wednesday it would subject 27 drugs to inflation penalties, a move that will reduce out-of-pocket costs for Medicare recipients by $2 to as much as $390 per average dose.
"Starting on April 1, Medicare beneficiaries will pay lower coinsura... | The list includes AbbVie Inc's ABBV.N blockbuster arthritis drug, Humira, Gilead Sciences Inc's GILD.O Car-T cancer therapy, Yescarta, and Seagen Inc's SGEN.O targeted cancer therapy, Padcev, the White House said in a fact sheet. By Ahmed Aboulenein WASHINGTON, March 15 (Reuters) - The U.S. government said on Wednesday... | The list includes AbbVie Inc's ABBV.N blockbuster arthritis drug, Humira, Gilead Sciences Inc's GILD.O Car-T cancer therapy, Yescarta, and Seagen Inc's SGEN.O targeted cancer therapy, Padcev, the White House said in a fact sheet. By Ahmed Aboulenein WASHINGTON, March 15 (Reuters) - The U.S. government said on Wednesday... | The list includes AbbVie Inc's ABBV.N blockbuster arthritis drug, Humira, Gilead Sciences Inc's GILD.O Car-T cancer therapy, Yescarta, and Seagen Inc's SGEN.O targeted cancer therapy, Padcev, the White House said in a fact sheet. By Ahmed Aboulenein WASHINGTON, March 15 (Reuters) - The U.S. government said on Wednesday... | The list includes AbbVie Inc's ABBV.N blockbuster arthritis drug, Humira, Gilead Sciences Inc's GILD.O Car-T cancer therapy, Yescarta, and Seagen Inc's SGEN.O targeted cancer therapy, Padcev, the White House said in a fact sheet. Companies that raise prices higher than the inflation rate will be required to pay Medicar... |
22,720 | 2023-03-15 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-1 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,721 | 2023-03-15 00:00:00 UTC | US to impose inflation fines on first set of drugs, lowering costs | ABBV | https://www.nasdaq.com/articles/us-to-impose-inflation-fines-on-first-set-of-drugs-lowering-costs | null | null | By Ahmed Aboulenein
WASHINGTON, March 15 (Reuters) - The U.S. government will subject 27 drugs to inflation penalties, it announced on Wednesday, meaning people on Medicare will pay less out-of-pocket by $2 to as high as $390 per average dose starting April 1.
President Joe Biden's signature Inflation Reduction Act inc... | The list includes AbbVie Inc's ABBV.N blockbuster arthritis drug Humira, Gilead Sciences Inc's GILD.O Car-T cancer therapy Yescarta and Seagen Inc's SGEN.O targeted cancer therapy Padcev, the White House said in a fact sheet. By Ahmed Aboulenein WASHINGTON, March 15 (Reuters) - The U.S. government will subject 27 drugs... | The list includes AbbVie Inc's ABBV.N blockbuster arthritis drug Humira, Gilead Sciences Inc's GILD.O Car-T cancer therapy Yescarta and Seagen Inc's SGEN.O targeted cancer therapy Padcev, the White House said in a fact sheet. By Ahmed Aboulenein WASHINGTON, March 15 (Reuters) - The U.S. government will subject 27 drugs... | The list includes AbbVie Inc's ABBV.N blockbuster arthritis drug Humira, Gilead Sciences Inc's GILD.O Car-T cancer therapy Yescarta and Seagen Inc's SGEN.O targeted cancer therapy Padcev, the White House said in a fact sheet. By Ahmed Aboulenein WASHINGTON, March 15 (Reuters) - The U.S. government will subject 27 drugs... | The list includes AbbVie Inc's ABBV.N blockbuster arthritis drug Humira, Gilead Sciences Inc's GILD.O Car-T cancer therapy Yescarta and Seagen Inc's SGEN.O targeted cancer therapy Padcev, the White House said in a fact sheet. President Joe Biden's signature Inflation Reduction Act includes a provision penalizing drugma... |
22,722 | 2023-03-14 00:00:00 UTC | UPRO, ABBV, LLY, BAC: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/upro-abbv-lly-bac%3A-large-outflows-detected-at-etf | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $75.7 million dollar outflow -- that's a 3.7% decrease week over week (from 64,200,000 to 61,850,000). Among th... | Among the largest underlying components of UPRO, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, Eli Lilly (Symbol: LLY) is up about 0.2%, and Bank of America Corp (Symbol: BAC) is up by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel... | Among the largest underlying components of UPRO, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, Eli Lilly (Symbol: LLY) is up about 0.2%, and Bank of America Corp (Symbol: BAC) is up by about 1.6%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price per... | Among the largest underlying components of UPRO, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, Eli Lilly (Symbol: LLY) is up about 0.2%, and Bank of America Corp (Symbol: BAC) is up by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel... | Among the largest underlying components of UPRO, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, Eli Lilly (Symbol: LLY) is up about 0.2%, and Bank of America Corp (Symbol: BAC) is up by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel... |
22,723 | 2023-03-14 00:00:00 UTC | The Zacks Analyst Blog Highlights AbbVie, NextEra Energy, ConocoPhillips, Canadian Pacific Railway and Intercontinental Exchange | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-abbvie-nextera-energy-conocophillips-canadian-pacific | null | null | For Immediate Release
Chicago, IL – March 14, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, NextEra En... | Stocks recently featured in the blog include: AbbVie Inc. ABBV, NextEra Energy, Inc. NEE, ConocoPhillips COP, Canadian Pacific Railway Ltd. CP and Intercontinental Exchange, Inc. ICE. Here are highlights from Monday’s Analyst Blog: Top Research Reports for AbbVie, NextEra and ConocoPhillips The Zacks Research Daily pre... | Stocks recently featured in the blog include: AbbVie Inc. ABBV, NextEra Energy, Inc. NEE, ConocoPhillips COP, Canadian Pacific Railway Ltd. CP and Intercontinental Exchange, Inc. ICE. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), NextEra Energy, Inc. (NEE) and Co... | Here are highlights from Monday’s Analyst Blog: Top Research Reports for AbbVie, NextEra and ConocoPhillips The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), NextEra Energy, Inc. (NEE) an... | Stocks recently featured in the blog include: AbbVie Inc. ABBV, NextEra Energy, Inc. NEE, ConocoPhillips COP, Canadian Pacific Railway Ltd. CP and Intercontinental Exchange, Inc. ICE. Here are highlights from Monday’s Analyst Blog: Top Research Reports for AbbVie, NextEra and ConocoPhillips The Zacks Research Daily pre... |
22,724 | 2023-03-14 00:00:00 UTC | 5 Forever Dividend Stocks | ABBV | https://www.nasdaq.com/articles/5-forever-dividend-stocks | null | null | All five of these dividend stocks are of the highest quality and they have a long track record of growing their dividend payouts. Two of the stocks are Dividend Kings and two have a AAA credit rating, one of those being Microsoft (NASDAQ: MSFT).
Check out this short video to learn more, consider subscribing to the chan... | See the 10 stocks *Stock Advisor returns as of March 8, 2023 Mark Roussin, CPA has positions in AbbVie, Coca-Cola, Johnson & Johnson, and Microsoft. Two of the stocks are Dividend Kings and two have a AAA credit rating, one of those being Microsoft (NASDAQ: MSFT). After all, the newsletter they have run for over a deca... | See the 10 stocks *Stock Advisor returns as of March 8, 2023 Mark Roussin, CPA has positions in AbbVie, Coca-Cola, Johnson & Johnson, and Microsoft. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. The Motley Fool recommends Johnson & Johnson and recommends t... | See the 10 stocks *Stock Advisor returns as of March 8, 2023 Mark Roussin, CPA has positions in AbbVie, Coca-Cola, Johnson & Johnson, and Microsoft. 10 stocks we like better than Microsoft When our award-winning analyst team has a stock tip, it can pay to listen. The Motley Fool recommends Johnson & Johnson and recomme... | See the 10 stocks *Stock Advisor returns as of March 8, 2023 Mark Roussin, CPA has positions in AbbVie, Coca-Cola, Johnson & Johnson, and Microsoft. The Motley Fool has positions in and recommends Home Depot and Microsoft. Their opinions remain their own and are unaffected by The Motley Fool. |
22,725 | 2023-03-14 00:00:00 UTC | Diversify Your Income with These 2 High-Yielding Dividend ETFs | ABBV | https://www.nasdaq.com/articles/diversify-your-income-with-these-2-high-yielding-dividend-etfs | null | null | Diversification is a term widely used when it comes to investing in the stock market. It means spreading your investment across different sectors and industries to minimize volatility's impact. While one segment may take a hit, another one may improve or take less of a hit. In a nutshell, don't put all of your eggs int... | The majority of its investments are in low beta names like insurance giant Progressive Corp. (NYSE: PGR), pharmaceutical giant AbbVie Inc. (NYSE: ABBV), and candle giant The Hershey Co. (NYSE: HSY). The beauty of this strategy (if done correctly) is that Nasdaq 100 technology stocks have more volatility and therefore c... | The majority of its investments are in low beta names like insurance giant Progressive Corp. (NYSE: PGR), pharmaceutical giant AbbVie Inc. (NYSE: ABBV), and candle giant The Hershey Co. (NYSE: HSY). For high-yield dividend investors, it means balancing risk with reward and spreading the investment through different ris... | The majority of its investments are in low beta names like insurance giant Progressive Corp. (NYSE: PGR), pharmaceutical giant AbbVie Inc. (NYSE: ABBV), and candle giant The Hershey Co. (NYSE: HSY). A high-yielding dividend ETF takes it one step further by upping the risk, so it may take another high-yielding dividend ... | The majority of its investments are in low beta names like insurance giant Progressive Corp. (NYSE: PGR), pharmaceutical giant AbbVie Inc. (NYSE: ABBV), and candle giant The Hershey Co. (NYSE: HSY). Investing in dividend exchange-traded-fund (ETFs) spreads the risk among different holdings within the ETF. This ETF inve... |
22,726 | 2023-03-13 00:00:00 UTC | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-as-market-dips%3A-what-you-should-know-7 | null | null | AbbVie (ABBV) closed the most recent trading day at $151.95, moving +1.5% from the previous trading session. This change outpaced the S&P 500's 0.15% loss on the day. Elsewhere, the Dow lost 0.28%, while the tech-heavy Nasdaq added 3.16%.
Heading into today, shares of the drugmaker had lost 1.54% over the past month, o... | AbbVie (ABBV) closed the most recent trading day at $151.95, moving +1.5% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. In that report, analysts expect AbbVie to post earnings of $2.50 per share. | AbbVie (ABBV) closed the most recent trading day at $151.95, moving +1.5% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. In that report, analysts expect AbbVie to post earnings of $2.50 per share. | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) closed the most recent trading day at $151.95, moving +1.5% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings re... | AbbVie currently has a Zacks Rank of #3 (Hold). AbbVie (ABBV) closed the most recent trading day at $151.95, moving +1.5% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. |
22,727 | 2023-03-13 00:00:00 UTC | Top Research Reports for AbbVie, NextEra Energy & ConocoPhillips | ABBV | https://www.nasdaq.com/articles/top-research-reports-for-abbvie-nextera-energy-conocophillips | null | null | Monday, March 13, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), NextEra Energy, Inc. (NEE) and ConocoPhillips (COP). These research reports have been hand-picked from the roughl... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Steady Investment & Renewable Focus Aid NextEra Energy (NEE) ConocoPhillips (COP) Banks On Oil-Rich Bakken Shale Assets Featured Reports Abbott's (AB... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Steady Investment & Renewable Focus Aid NextEra Energy (NEE) ConocoPhillips (COP) Banks On Oil-Rich Bakken Shale Assets Featured Reports Abbott's (AB... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Steady Investment & Renewable Focus Aid NextEra Energy (NEE) ConocoPhillips (COP) Banks On Oil-Rich Bakken Shale Assets Featured Reports Abbott's (AB... | Click to get this free report NextEra Energy, Inc. (NEE) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Intercontinental Exchange Inc. (ICE) : Free Stock Analysis Report ConocoPhillips (COP) : Free Stock Analysis Report Canadian Pacific Railway Limited (CP) : Free Stock Analysis Rep... |
22,728 | 2023-03-13 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-0 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,729 | 2023-03-13 00:00:00 UTC | Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation | ABBV | https://www.nasdaq.com/articles/bristol-myers-pfizer-abbvie-drugs-likely-to-face-u.s.-price-negotiation | null | null | By Michael Erman, Patrick Wingrove and Ahmed Aboulenein
NEW YORK/WASHINGTON, March 13 (Reuters) - The blood thinner Eliquis from Bristol Myers Squibb, Pfizer's breast cancer drug Ibrance and AbbVie's leukemia treatment Imbruvica are likely to be among 10 big-selling medicines subject to U.S. price negotiations for 2026... | By Michael Erman, Patrick Wingrove and Ahmed Aboulenein NEW YORK/WASHINGTON, March 13 (Reuters) - The blood thinner Eliquis from Bristol Myers Squibb, Pfizer's breast cancer drug Ibrance and AbbVie's leukemia treatment Imbruvica are likely to be among 10 big-selling medicines subject to U.S. price negotiations for 2026... | By Michael Erman, Patrick Wingrove and Ahmed Aboulenein NEW YORK/WASHINGTON, March 13 (Reuters) - The blood thinner Eliquis from Bristol Myers Squibb, Pfizer's breast cancer drug Ibrance and AbbVie's leukemia treatment Imbruvica are likely to be among 10 big-selling medicines subject to U.S. price negotiations for 2026... | By Michael Erman, Patrick Wingrove and Ahmed Aboulenein NEW YORK/WASHINGTON, March 13 (Reuters) - The blood thinner Eliquis from Bristol Myers Squibb, Pfizer's breast cancer drug Ibrance and AbbVie's leukemia treatment Imbruvica are likely to be among 10 big-selling medicines subject to U.S. price negotiations for 2026... | By Michael Erman, Patrick Wingrove and Ahmed Aboulenein NEW YORK/WASHINGTON, March 13 (Reuters) - The blood thinner Eliquis from Bristol Myers Squibb, Pfizer's breast cancer drug Ibrance and AbbVie's leukemia treatment Imbruvica are likely to be among 10 big-selling medicines subject to U.S. price negotiations for 2026... |
22,730 | 2023-03-13 00:00:00 UTC | Galderma posts 2022 revenue growth ahead of planned IPO | ABBV | https://www.nasdaq.com/articles/galderma-posts-2022-revenue-growth-ahead-of-planned-ipo | null | null | By Emma-Victoria Farr
FRANKFURT, March 13 (Reuters) - Swiss dermatology company Galderma posted $3.8 billion in net sales during 2022, up 13.9% on 2021 on a constant currency basis, driven by growth in its injectable aesthetics and dermatological skincare units.
The results come ahead of a possible initial public offer... | In injectables this includes Allergan, a subsidiary of AbbVie ABBV.N, for dermatological skincare L'Oreal OREP.PA and for atopic dermatitis (eczema) Sanofi SASY.PA among others, Ornskov said. "Galderma is run like a public company and we are prepared for the next step," Ornskov said, declining to give details on valuat... | In injectables this includes Allergan, a subsidiary of AbbVie ABBV.N, for dermatological skincare L'Oreal OREP.PA and for atopic dermatitis (eczema) Sanofi SASY.PA among others, Ornskov said. By Emma-Victoria Farr FRANKFURT, March 13 (Reuters) - Swiss dermatology company Galderma posted $3.8 billion in net sales during... | In injectables this includes Allergan, a subsidiary of AbbVie ABBV.N, for dermatological skincare L'Oreal OREP.PA and for atopic dermatitis (eczema) Sanofi SASY.PA among others, Ornskov said. By Emma-Victoria Farr FRANKFURT, March 13 (Reuters) - Swiss dermatology company Galderma posted $3.8 billion in net sales during... | In injectables this includes Allergan, a subsidiary of AbbVie ABBV.N, for dermatological skincare L'Oreal OREP.PA and for atopic dermatitis (eczema) Sanofi SASY.PA among others, Ornskov said. By Emma-Victoria Farr FRANKFURT, March 13 (Reuters) - Swiss dermatology company Galderma posted $3.8 billion in net sales during... |
22,731 | 2023-03-11 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,732 | 2023-03-11 00:00:00 UTC | 3 No-Brainer Dividend Stocks to Buy in March | ABBV | https://www.nasdaq.com/articles/3-no-brainer-dividend-stocks-to-buy-in-march | null | null | Some decisions are painstakingly difficult. Others are downright easy. Choosing from the thousands of dividend stocks on the market can fall into the former category. But it doesn't have to.
Three Fool.com contributors selected dividend stocks they believe are no-brainer picks to buy in March. Here's why they chose Abb... | Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). A better picture than meets the eye Keith Speights (AbbVie): I don't think anyone would seriously challenge AbbVie's credentials as a solid dividend stock. AbbVie's dividend yield stands at nearly 4%. | Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). A better picture than meets the eye Keith Speights (AbbVie): I don't think anyone would seriously challenge AbbVie's credentials as a solid dividend stock. AbbVie's dividend yield stands at nearly 4%. | Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). A better picture than meets the eye Keith Speights (AbbVie): I don't think anyone would seriously challenge AbbVie's credentials as a solid dividend stock. AbbVie's dividend yield stands at nearly 4%. | AbbVie's dividend yield stands at nearly 4%. Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE). A better picture than meets the eye Keith Speights (AbbVie): I don't think anyone would seriously challenge AbbVie's credentials as a solid dividend stock. |
22,733 | 2023-03-10 00:00:00 UTC | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | ABBV | https://www.nasdaq.com/articles/investors-heavily-search-abbvie-inc.-abbv%3A-here-is-what-you-need-to-know-4 | null | null | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned -0.9% over the past month versus the Zacks S&P 500 composite's -3.8% chan... | Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVi... | Last Reported Results and Surprise History AbbVie reported revenues of $15.12 billion in the last reported quarter, representing a year-over-year change of +1.6%. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has l... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs... |
22,734 | 2023-03-10 00:00:00 UTC | U.S. FDA approves Pfizer's nasal spray for migraine | ABBV | https://www.nasdaq.com/articles/u.s.-fda-approves-pfizers-nasal-spray-for-migraine-0 | null | null | Adds background
March 10 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved Pfizer Inc's PFE.N nasal spray for migraine, giving patients access to a potentially fast-acting option to treat their headaches.
The drug Zavzpret, also known as zavegepant, was approved for the treatment of acute migra... | Zavzpret belongs to a class of drugs called calcitonin gene-related peptide (CGRP) inhibitors and will compete with other therapies from AbbVie Inc ABBV.O, Eli Lilly and Co LLY.N, Amgen Inc AMGN.O and Teva Pharmaceutical TEVA.TA. Adds background March 10 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday... | Zavzpret belongs to a class of drugs called calcitonin gene-related peptide (CGRP) inhibitors and will compete with other therapies from AbbVie Inc ABBV.O, Eli Lilly and Co LLY.N, Amgen Inc AMGN.O and Teva Pharmaceutical TEVA.TA. Adds background March 10 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday... | Zavzpret belongs to a class of drugs called calcitonin gene-related peptide (CGRP) inhibitors and will compete with other therapies from AbbVie Inc ABBV.O, Eli Lilly and Co LLY.N, Amgen Inc AMGN.O and Teva Pharmaceutical TEVA.TA. Adds background March 10 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday... | Zavzpret belongs to a class of drugs called calcitonin gene-related peptide (CGRP) inhibitors and will compete with other therapies from AbbVie Inc ABBV.O, Eli Lilly and Co LLY.N, Amgen Inc AMGN.O and Teva Pharmaceutical TEVA.TA. Adds background March 10 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday... |
22,735 | 2023-03-10 00:00:00 UTC | Zacks Investment Ideas feature highlights: Coca-Cola Company, AbbVie and Exxon Mobil | ABBV | https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-coca-cola-company-abbvie-and-exxon-mobil | null | null | For Immediate Release
Chicago, IL – March 10, 2023 – Today, Zacks Investment Ideas feature highlights Coca-Cola Company KO, AbbVie ABBV and Exxon Mobil XOM.
Reap Monthly Income with This 3-Stock Combo
While the majority of stocks pay quarterly dividends, investors can still construct a portfolio that allows them to get... | For Immediate Release Chicago, IL – March 10, 2023 – Today, Zacks Investment Ideas feature highlights Coca-Cola Company KO, AbbVie ABBV and Exxon Mobil XOM. In addition, AbbVie’s cash-generating abilities have been amplified thanks to successful new drugs; ABBV generated $7.2 billion of free cash flow in its latest qua... | For Immediate Release Chicago, IL – March 10, 2023 – Today, Zacks Investment Ideas feature highlights Coca-Cola Company KO, AbbVie ABBV and Exxon Mobil XOM. When combined, all three stocks above – Coca-Cola Company, AbbVie and Exxon Mobil – construct a portfolio that allows monthly income. Click to get this free report... | For Immediate Release Chicago, IL – March 10, 2023 – Today, Zacks Investment Ideas feature highlights Coca-Cola Company KO, AbbVie ABBV and Exxon Mobil XOM. Click to get this free report CocaCola Company (The) (KO) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report AbbVie Inc. (ABBV... | When combined, all three stocks above – Coca-Cola Company, AbbVie and Exxon Mobil – construct a portfolio that allows monthly income. For Immediate Release Chicago, IL – March 10, 2023 – Today, Zacks Investment Ideas feature highlights Coca-Cola Company KO, AbbVie ABBV and Exxon Mobil XOM. Together, three stocks – Coca... |
22,736 | 2023-03-09 00:00:00 UTC | Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-wisdomtree-u.s.-high-dividend-etf-dhs-a-strong-etf-right-now-5 | null | null | The WisdomTree U.S. High Dividend ETF (DHS) made its debut on 06/16/2006, and is a smart beta exchange traded fund that provides broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
The ETF industry has long been dominated by products based on market cap weighted indexes, ... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.10% of total assets, followed by Abbvie Inc (ABBV) and Pfizer Inc (PFE). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Pfizer Inc. (PFE) : ... | Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 1000 Value ... | Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 1000 Value ... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.10% of total assets, followed by Abbvie Inc (ABBV) and Pfizer Inc (PFE). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Pfizer Inc. (PFE) : ... |
22,737 | 2023-03-09 00:00:00 UTC | Surprising Analyst 12-Month Target For HUSV | ABBV | https://www.nasdaq.com/articles/surprising-analyst-12-month-target-for-husv | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Horizon Managed Vol... | First Trust Horizon Managed Volatility Domestic ETF HUSV $31.84 $34.99 9.89% AbbVie Inc ABBV $149.60 $165.73 10.78% AutoZone, Inc. AZO $2459.57 $2724.19 10.76% Quest Diagnostics, Inc. DGX $136.73 $150.58 10.13% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 mon... | Three of HUSV's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), AutoZone, Inc. (Symbol: AZO), and Quest Diagnostics, Inc. (Symbol: DGX). First Trust Horizon Managed Volatility Domestic ETF HUSV $31.84 $34.99 9.89% AbbVie Inc ABBV $149.60 $165.73 10.78% AutoZone, Inc... | Three of HUSV's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), AutoZone, Inc. (Symbol: AZO), and Quest Diagnostics, Inc. (Symbol: DGX). Although ABBV has traded at a recent price of $149.60/share, the average analyst target is 10.78% higher at $165.73/share. Below ... | First Trust Horizon Managed Volatility Domestic ETF HUSV $31.84 $34.99 9.89% AbbVie Inc ABBV $149.60 $165.73 10.78% AutoZone, Inc. AZO $2459.57 $2724.19 10.76% Quest Diagnostics, Inc. DGX $136.73 $150.58 10.13% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 mon... |
22,738 | 2023-03-09 00:00:00 UTC | Guru Fundamental Report for ABBV - Partha Mohanram | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-partha-mohanram | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,739 | 2023-03-09 00:00:00 UTC | Is It Too Late to Buy AbbVie Stock? | ABBV | https://www.nasdaq.com/articles/is-it-too-late-to-buy-abbvie-stock-1 | null | null | AbbVie (NYSE: ABBV) has shown itself to be a great long-term investment. The drugmaker's shares have climbed about 300% over the past decade. And earnings have soared, thanks to the company's blockbuster immunology drug Humira.
But things are changing at AbbVie. Humira already has been facing competition internationall... | But there's also reason to see this as a temporary problem, and one with a solution just ahead -- AbbVie's newer immunology drugs Rinvoq and Skyrizi. AbbVie (NYSE: ABBV) has shown itself to be a great long-term investment. But things are changing at AbbVie. | AbbVie (NYSE: ABBV) has shown itself to be a great long-term investment. But things are changing at AbbVie. So now the question is: Is it too late to buy AbbVie stock? | And they're on the way to meeting AbbVie's big goal: The company says that together, they will generate more than $21 billion in annual revenue by 2027. Last year, AbbVie's neuroscience portfolio posted double-digit growth to deliver more than $6.5 billion in revenue. We can expect a pause in growth this year or next y... | AbbVie (NYSE: ABBV) has shown itself to be a great long-term investment. But things are changing at AbbVie. So now the question is: Is it too late to buy AbbVie stock? |
22,740 | 2023-03-09 00:00:00 UTC | 3 High-Yield Dividend Stocks to Buy Before the Next Bull Rally | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-to-buy-before-the-next-bull-rally | null | null | The current bear market has been brutal for investors of all kinds. Even shares of well-established businesses that are components of the S&P 500 index haven't escaped the beatings. The benchmark index is down around 17% from the peak it reached more than a year ago.
The market's dismal performance since the end of 202... | AbbVie AbbVie (NYSE: ABBV) is another dividend grower that was spun off from a much larger business. AbbVie began as the pharmaceutical segment of Abbott Laboratories but the conglomerate spun AbbVie off into a separate entity in 2013. Lower-cost biosimilar versions of the injection finally launched this January, and t... | AbbVie AbbVie (NYSE: ABBV) is another dividend grower that was spun off from a much larger business. AbbVie began as the pharmaceutical segment of Abbott Laboratories but the conglomerate spun AbbVie off into a separate entity in 2013. Lower-cost biosimilar versions of the injection finally launched this January, and t... | AbbVie AbbVie (NYSE: ABBV) is another dividend grower that was spun off from a much larger business. AbbVie began as the pharmaceutical segment of Abbott Laboratories but the conglomerate spun AbbVie off into a separate entity in 2013. Lower-cost biosimilar versions of the injection finally launched this January, and t... | In recent years, AbbVie has launched new blockbuster drugs that can more than offset impending Humira losses. AbbVie AbbVie (NYSE: ABBV) is another dividend grower that was spun off from a much larger business. AbbVie began as the pharmaceutical segment of Abbott Laboratories but the conglomerate spun AbbVie off into a... |
22,741 | 2023-03-09 00:00:00 UTC | 3 Surefire Stocks That Are Screaming Buys in March | ABBV | https://www.nasdaq.com/articles/3-surefire-stocks-that-are-screaming-buys-in-march | null | null | For long-term investors, growth stocks are a superior option in a volatile market. Long-term investors can afford to be far less concerned with short-term fluctuations in stock prices. Growth stocks generally take time to show their full potential, so they tend to be good options for patient investors with a high appet... | Regardless of how their stocks perform at the moment, biopharma company AbbVie (NYSE: ABBV) and cannabis companies Green Thumb Industries (OTC: GTBIF) and Tilray Brands (NASDAQ: TLRY) appear to be in prime position for investing. AbbVie has a strong portfolio of quality drugs Investors became wary of AbbVie stock after... | Regardless of how their stocks perform at the moment, biopharma company AbbVie (NYSE: ABBV) and cannabis companies Green Thumb Industries (OTC: GTBIF) and Tilray Brands (NASDAQ: TLRY) appear to be in prime position for investing. AbbVie has a strong portfolio of quality drugs Investors became wary of AbbVie stock after... | Regardless of how their stocks perform at the moment, biopharma company AbbVie (NYSE: ABBV) and cannabis companies Green Thumb Industries (OTC: GTBIF) and Tilray Brands (NASDAQ: TLRY) appear to be in prime position for investing. AbbVie has a strong portfolio of quality drugs Investors became wary of AbbVie stock after... | AbbVie has a strong portfolio of quality drugs Investors became wary of AbbVie stock after the company's star pharmaceutical, Humira, lost patent exclusivity in the U.S. at the start of 2023. AbbVie is a growth stock, but it is also an income stock. Regardless of how their stocks perform at the moment, biopharma compan... |
22,742 | 2023-03-08 00:00:00 UTC | Noteworthy Wednesday Option Activity: ANET, ABBV, ASAN | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-anet-abbv-asan | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Arista Networks Inc (Symbol: ANET), where a total volume of 10,002 contracts has been traded thus far today, a contract volume which is representative of approximately 1.0 million underlying shares (giv... | Particularly high volume was seen for the $160 strike call option expiring March 17, 2023, with 9,148 contracts trading so far today, representing approximately 914,800 underlying shares of ABBV. Below is a chart showing ANET's trailing twelve month trading history, with the $145 strike highlighted in orange: AbbVie In... | Below is a chart showing ANET's trailing twelve month trading history, with the $145 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 25,641 contracts thus far today. Below is a chart showing ABBV's trailing twelve month trading history, with the $160 strike highlighted in orange:... | That number of contracts represents approximately 2.6 million underlying shares, working out to a sizeable 42.5% of ABBV's average daily trading volume over the past month, of 6.0 million shares. Below is a chart showing ABBV's trailing twelve month trading history, with the $160 strike highlighted in orange: And Asana... | Particularly high volume was seen for the $160 strike call option expiring March 17, 2023, with 9,148 contracts trading so far today, representing approximately 914,800 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $160 strike highlighted in orange: And Asana... |
22,743 | 2023-03-07 00:00:00 UTC | The Stock That Tripled in a Day...And May Not Be Done | ABBV | https://www.nasdaq.com/articles/the-stock-that-tripled-in-a-day...and-may-not-be-done | null | null | Texas-based biotechnology company Reata Pharmaceuticals, Inc. (NASDAQ:RETA) lulled shareholders to sleep in 2022. The news flow was light, the trading pattern sideways and volume virtually nonexistent.
Things changed in dramatic fashion last week.
On February 28th, the U.S. Food and Drug Administration (FDA) approved ... | In 2022, the company earned around $2 million in collaboration revenue tied to its relationships with AbbVie and Japan’s Kyowa Kirin. On February 28th, the U.S. Food and Drug Administration (FDA) approved Reata’s lead candidate Skyclarys for the treatment of patients with an inherited neuromuscular disease called Fried... | In 2022, the company earned around $2 million in collaboration revenue tied to its relationships with AbbVie and Japan’s Kyowa Kirin. Texas-based biotechnology company Reata Pharmaceuticals, Inc. (NASDAQ:RETA) lulled shareholders to sleep in 2022. On February 28th, the U.S. Food and Drug Administration (FDA) approved R... | In 2022, the company earned around $2 million in collaboration revenue tied to its relationships with AbbVie and Japan’s Kyowa Kirin. On February 28th, the U.S. Food and Drug Administration (FDA) approved Reata’s lead candidate Skyclarys for the treatment of patients with an inherited neuromuscular disease called Fried... | In 2022, the company earned around $2 million in collaboration revenue tied to its relationships with AbbVie and Japan’s Kyowa Kirin. Trading volume was 15x the stock’s average over the previous 90 days. Should investors covet the stock for their portfolios? |
22,744 | 2023-03-07 00:00:00 UTC | Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-wisdomtree-u.s.-high-dividend-etf-dhs-be-on-your-investing-radar-6 | null | null | The WisdomTree U.S. High Dividend ETF (DHS) was launched on 06/16/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by Wisdomtree. It has amassed assets over $1.48 billion, making it one of the average siz... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.10% of total assets, followed by Abbvie Inc (ABBV) and Pfizer Inc (PFE). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Pfizer Inc. (PFE) : ... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.10% of total assets, followed by Abbvie Inc (ABBV) and Pfizer Inc (PFE). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Pfizer Inc. (PFE) : ... | Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports iShares Russell 1000 Value ... | Looking at individual holdings, Exxon Mobil Corp (XOM) accounts for about 5.10% of total assets, followed by Abbvie Inc (ABBV) and Pfizer Inc (PFE). Click to get this free report WisdomTree U.S. High Dividend ETF (DHS): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Pfizer Inc. (PFE) : ... |
22,745 | 2023-03-06 00:00:00 UTC | 7 Dividend Kings to Buy for an Uncertain Market Environment | ABBV | https://www.nasdaq.com/articles/7-dividend-kings-to-buy-for-an-uncertain-market-environment | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Though the term dividend aristocrats generate plenty of interest for the underlying elite status, another even more rarefied category exists called dividend kings to buy. Rather than 25 years of consecutive payout growth, the kings command at least 50 years... | ABBV AbbVie $155.28 CL Colgate-Palmolive $73.29 PG Procter & Gamble $140.35 NWN Northwest Natural $47.41 KO Coca-Cola $60.36 JNJ Johnson & Johnson $155.56 AbbVie (ABBV) Source: Sisacorn / Shutterstock.com A top-flight pharmaceutical firm, AbbVie (NYSE:ABBV) ranks among the most intriguing dividend kings to buy. Now, it... | ABBV AbbVie $155.28 CL Colgate-Palmolive $73.29 PG Procter & Gamble $140.35 NWN Northwest Natural $47.41 KO Coca-Cola $60.36 JNJ Johnson & Johnson $155.56 AbbVie (ABBV) Source: Sisacorn / Shutterstock.com A top-flight pharmaceutical firm, AbbVie (NYSE:ABBV) ranks among the most intriguing dividend kings to buy. Now, it... | JNJ Johnson & Johnson $155.56 AbbVie (ABBV) Source: Sisacorn / Shutterstock.com A top-flight pharmaceutical firm, AbbVie (NYSE:ABBV) ranks among the most intriguing dividend kings to buy. ABBV AbbVie $155.28 CL Colgate-Palmolive $73.29 PG Procter & Gamble $140.35 NWN Northwest Natural $47.41 KO Coca-Cola $60.36 Now, it... | ABBV AbbVie $155.28 CL Colgate-Palmolive $73.29 PG Procter & Gamble $140.35 NWN Northwest Natural $47.41 KO Coca-Cola $60.36 JNJ Johnson & Johnson $155.56 AbbVie (ABBV) Source: Sisacorn / Shutterstock.com A top-flight pharmaceutical firm, AbbVie (NYSE:ABBV) ranks among the most intriguing dividend kings to buy. Now, it... |
22,746 | 2023-03-06 00:00:00 UTC | VTV, ABBV, PFE, BAC: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/vtv-abbv-pfe-bac%3A-etf-inflow-alert | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $884.6 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 726,197,049 to 732,433... | Among the largest underlying components of VTV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Pfizer Inc (Symbol: PFE) is down about 0.2%, and Bank of America Corp (Symbol: BAC) is up by about 1%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to acc... | Among the largest underlying components of VTV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Pfizer Inc (Symbol: PFE) is down about 0.2%, and Bank of America Corp (Symbol: BAC) is up by about 1%. For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price pe... | Among the largest underlying components of VTV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Pfizer Inc (Symbol: PFE) is down about 0.2%, and Bank of America Corp (Symbol: BAC) is up by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chann... | Among the largest underlying components of VTV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.5%, Pfizer Inc (Symbol: PFE) is down about 0.2%, and Bank of America Corp (Symbol: BAC) is up by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chann... |
22,747 | 2023-03-04 00:00:00 UTC | Validea Guru Fundamental Report for ABBV - 3/4/2023 | ABBV | https://www.nasdaq.com/articles/validea-guru-fundamental-report-for-abbv-3-4-2023 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,748 | 2023-03-04 00:00:00 UTC | 2 Top Dividend Kings to Buy for the Long Haul | ABBV | https://www.nasdaq.com/articles/2-top-dividend-kings-to-buy-for-the-long-haul-4 | null | null | Dividend Kings are among the best stocks that income-seeking investors can turn to in these uncertain days. These companies have been raising their payouts for at least 50 consecutive years, which says something about the strength of their underlying businesses. And beyond the potential for the regular passive income t... | Although its most important product over this period, rheumatoid arthritis drug Humira, is now facing biosimilar competition, AbbVie can rely on other blockbusters to pick up the slack. Beyond its immunology products, AbbVie has a deep lineup that includes cancer drugs Venclexta and Imbruvica, its Botox franchise, depr... | Let's consider a duo of corporations in this category that investors should consider buying and holding on to for a while: Abbott Laboratories (NYSE: ABT) and AbbVie (NYSE: ABBV). AbbVie AbbVie is a drugmaker with 51 years of consecutive dividend increases. AbbVie was once a division of Abbott Laboratories. | Even at a 50% success rate, that's two dozen brand-new products or label expansions AbbVie can score in the next few years, at least a handful of which will meaningfully impact revenue growth for years. Let's consider a duo of corporations in this category that investors should consider buying and holding on to for a w... | Let's consider a duo of corporations in this category that investors should consider buying and holding on to for a while: Abbott Laboratories (NYSE: ABT) and AbbVie (NYSE: ABBV). AbbVie AbbVie is a drugmaker with 51 years of consecutive dividend increases. AbbVie was once a division of Abbott Laboratories. |
22,749 | 2023-03-04 00:00:00 UTC | 2 High-Yield Dividend Stocks to Buy in March | ABBV | https://www.nasdaq.com/articles/2-high-yield-dividend-stocks-to-buy-in-march | null | null | Hunting for the next big thing is an exciting investment strategy that usually doesn't work out. Luckily, there's a more reliable way to build wealth through the stock market.
If you're more interested in accumulating wealth than impressing folks with prescient stock market picks, consider these dividend-paying stocks.... | AbbVie AbbVie (NYSE: ABBV) only has a decade of consecutive annual-dividend raises under its belt because before that, it was the biopharmaceutical segment of Abbott Laboratories. Abbott had already been raising its payout for decades before the separation, and AbbVie picked up the pace. At recent prices, AbbVie shares... | AbbVie AbbVie (NYSE: ABBV) only has a decade of consecutive annual-dividend raises under its belt because before that, it was the biopharmaceutical segment of Abbott Laboratories. Abbott had already been raising its payout for decades before the separation, and AbbVie picked up the pace. At recent prices, AbbVie shares... | At recent prices, AbbVie shares offer a 3.8% yield that is way above the 1.7% yield offered by the average dividend-paying stock in the S&P 500 index. AbbVie AbbVie (NYSE: ABBV) only has a decade of consecutive annual-dividend raises under its belt because before that, it was the biopharmaceutical segment of Abbott Lab... | AbbVie AbbVie (NYSE: ABBV) only has a decade of consecutive annual-dividend raises under its belt because before that, it was the biopharmaceutical segment of Abbott Laboratories. Abbott had already been raising its payout for decades before the separation, and AbbVie picked up the pace. At recent prices, AbbVie shares... |
22,750 | 2023-03-02 00:00:00 UTC | Intel Slashed Its Dividend, But These 3 Yields Are Likely to Continue Rising | ABBV | https://www.nasdaq.com/articles/intel-slashed-its-dividend-but-these-3-yields-are-likely-to-continue-rising | null | null | In February, Intel (NASDAQ: INTC) rocked the markets with news that it was slashing its dividend by a mammoth 66%. That's a huge blow to investors who counted on that dividend. The danger ultimately comes down to cash flow as Intel was burning through cash from its day-to-day operations, and that is a huge red flag for... | Three dividend stocks that look to be in much better shape and have stronger cash flows than Intel are AbbVie (NYSE: ABBV), Costco Wholesale (NASDAQ: COST), and Microsoft (NASDAQ: MSFT). AbbVie Drugmaker AbbVie is a Dividend King known for raising its payouts on a regular basis. This year, AbbVie is projecting that its... | Three dividend stocks that look to be in much better shape and have stronger cash flows than Intel are AbbVie (NYSE: ABBV), Costco Wholesale (NASDAQ: COST), and Microsoft (NASDAQ: MSFT). AbbVie Drugmaker AbbVie is a Dividend King known for raising its payouts on a regular basis. This year, AbbVie is projecting that its... | Three dividend stocks that look to be in much better shape and have stronger cash flows than Intel are AbbVie (NYSE: ABBV), Costco Wholesale (NASDAQ: COST), and Microsoft (NASDAQ: MSFT). AbbVie Drugmaker AbbVie is a Dividend King known for raising its payouts on a regular basis. This year, AbbVie is projecting that its... | Three dividend stocks that look to be in much better shape and have stronger cash flows than Intel are AbbVie (NYSE: ABBV), Costco Wholesale (NASDAQ: COST), and Microsoft (NASDAQ: MSFT). AbbVie Drugmaker AbbVie is a Dividend King known for raising its payouts on a regular basis. This year, AbbVie is projecting that its... |
22,751 | 2023-03-02 00:00:00 UTC | RHHBY vs. ABBV: Which Stock Is the Better Value Option? | ABBV | https://www.nasdaq.com/articles/rhhby-vs.-abbv%3A-which-stock-is-the-better-value-option | null | null | Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Roche Holding AG (RHHBY) and AbbVie (ABBV). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
Everyone has their own methods for finding great val... | Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Roche Holding AG (RHHBY) and AbbVie (ABBV). Currently, Roche Holding AG has a Zacks Rank of #2 (Buy), while AbbVie has a Zacks Rank of #4 (Sell). RHHBY currently has a forward P/E ratio of 13.87, while ABBV has a for... | Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Roche Holding AG (RHHBY) and AbbVie (ABBV). Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click ... | These metrics, and several others, help RHHBY earn a Value grade of B, while ABBV has been given a Value grade of C. RHHBY has seen stronger estimate revision activity and sports more attractive valuation metrics than ABBV, so it seems like value investors will conclude that RHHBY is the superior option right now. Clic... | Currently, Roche Holding AG has a Zacks Rank of #2 (Buy), while AbbVie has a Zacks Rank of #4 (Sell). ABBV currently has a PEG ratio of 3.50. These metrics, and several others, help RHHBY earn a Value grade of B, while ABBV has been given a Value grade of C. RHHBY has seen stronger estimate revision activity and sports... |
22,752 | 2023-03-02 00:00:00 UTC | Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor | ABBV | https://www.nasdaq.com/articles/wall-street-sees-23-upside-in-revance-maker-of-botox-competitor | null | null | Investors in Revance Therapeutics Inc. (NASDAQ: RVNC) shouldn’t have much to frown about after the stock gapped up 54.34% on January 9, and built upon those gains in February.
Is this a stock to keep an eye on due to its strong future potential?
Shares fell on March 1 following the company’s fourth-quarter earnings r... | Daxxify has similarities to AbbVie Inc.’s (NYSE: ABBV) Botox in that both use a botulinum toxin as part of a neuromodulator, which affects how nerves work. One of those applications got the OK in January when the FDA approved Daxxify’s use to treat cervical dystonia, a painful condition in which a patient’s neck muscle... | Daxxify has similarities to AbbVie Inc.’s (NYSE: ABBV) Botox in that both use a botulinum toxin as part of a neuromodulator, which affects how nerves work. However, the revenue of $49.92 million topped analysts’ consensus views by 6.62%. On January 9, the day the stock gapped more than 54% higher, as you can see on its... | Daxxify has similarities to AbbVie Inc.’s (NYSE: ABBV) Botox in that both use a botulinum toxin as part of a neuromodulator, which affects how nerves work. On January 9, the day the stock gapped more than 54% higher, as you can see on its chart, the company said it expected preliminary unaudited Daxxify revenue from Pr... | Daxxify has similarities to AbbVie Inc.’s (NYSE: ABBV) Botox in that both use a botulinum toxin as part of a neuromodulator, which affects how nerves work. However, the revenue of $49.92 million topped analysts’ consensus views by 6.62%. One of those applications got the OK in January when the FDA approved Daxxify’s us... |
22,753 | 2023-03-02 00:00:00 UTC | These 2 Dividend Stocks Could Be a Great Addition to Your Income Portfolio | ABBV | https://www.nasdaq.com/articles/these-2-dividend-stocks-could-be-a-great-addition-to-your-income-portfolio | null | null | If you're interested in generating stable dividend income today as well as in the future, you'll need to look for a very particular kind of investment. Most companies don't have the benefit of rock-solid cash flows every quarter, nor do most have the confidence in their long-term growth to continue to give shareholders... | But now that Humira is getting its market share eroded by generic copies since the expiry of its exclusivity protections in 2023, other medicines will be driving AbbVie's growth -- and that's something key for dividend investors to appreciate about the stock. AbbVie With a total return of 519% over the last 10 years, A... | Realty Income Realty Income (NYSE: O) is quite different from AbbVie as it's a real estate investment trust (REIT). AbbVie With a total return of 519% over the last 10 years, AbbVie (NYSE: ABBV) is a dividend stock that also has a habit of handily beating the market. But now that Humira is getting its market share erod... | AbbVie With a total return of 519% over the last 10 years, AbbVie (NYSE: ABBV) is a dividend stock that also has a habit of handily beating the market. But now that Humira is getting its market share eroded by generic copies since the expiry of its exclusivity protections in 2023, other medicines will be driving AbbVie... | Realty Income Realty Income (NYSE: O) is quite different from AbbVie as it's a real estate investment trust (REIT). 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. AbbVie With a total return of 519% over the last 10 years, AbbVie (NYSE: ABBV) is a dividend... |
22,754 | 2023-03-01 00:00:00 UTC | 3 Top Defensive Stocks to Own for a Focus on Quality | ABBV | https://www.nasdaq.com/articles/3-top-defensive-stocks-to-own-for-a-focus-on-quality | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In today’s volatile and uncertain market, investors increasingly seek stable, reliable, and resilient companies to add to their portfolios. Defensive stocks, which are typically associated with companies that operate in industries that provide essential goo... | Ticker Company Price MCD McDonald’s $262.68 ABBV AbbVie $153.83 AWK American Water Works $139.55 McDonald’s (MCD) Source: 8th.creator / Shutterstock.com As far as defensive stocks are concerned, McDonald’s (NYSE:MCD) is a well-loved classic. AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Among the impressi... | Ticker Company Price MCD McDonald’s $262.68 ABBV AbbVie $153.83 AWK American Water Works $139.55 McDonald’s (MCD) Source: 8th.creator / Shutterstock.com As far as defensive stocks are concerned, McDonald’s (NYSE:MCD) is a well-loved classic. AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Among the impressi... | Ticker Company Price MCD McDonald’s $262.68 ABBV AbbVie $153.83 AWK American Water Works $139.55 McDonald’s (MCD) Source: 8th.creator / Shutterstock.com As far as defensive stocks are concerned, McDonald’s (NYSE:MCD) is a well-loved classic. AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Among the impressi... | Moreover, ABBV has increased its quarterly dividend to $1.48 per share from $1.41, resulting in a current yield of slightly below 4%. Ticker Company Price MCD McDonald’s $262.68 ABBV AbbVie $153.83 AWK American Water Works $139.55 McDonald’s (MCD) Source: 8th.creator / Shutterstock.com As far as defensive stocks are co... |
22,755 | 2023-03-01 00:00:00 UTC | Validea Guru Fundamental Report for ABBV - 3/1/2023 | ABBV | https://www.nasdaq.com/articles/validea-guru-fundamental-report-for-abbv-3-1-2023 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,756 | 2023-03-01 00:00:00 UTC | 3 Value Stocks You'll Regret Not Buying on the Dip | ABBV | https://www.nasdaq.com/articles/3-value-stocks-youll-regret-not-buying-on-the-dip | null | null | Value stocks are poised for a strong decade. The simple reason is that the Federal Reserve is highly unlikely to spur another growth stock boom by lowering interest rates to the effective floor in the years ahead.
Which value stocks are best positioned to capitalize on this favorable long-term dynamic? These three unde... | AbbVie Developing a blockbuster medication (a drug with greater than $1 billion in annual sales) requires a tremendous amount of talent, hard work, cash, and flat-out luck across every single layer of the pharma value chain (preclinical studies, human trials, regulatory affairs, and marketing). In addition, AbbVie deve... | AbbVie Developing a blockbuster medication (a drug with greater than $1 billion in annual sales) requires a tremendous amount of talent, hard work, cash, and flat-out luck across every single layer of the pharma value chain (preclinical studies, human trials, regulatory affairs, and marketing). AbbVie (NYSE: ABBV) is g... | Despite all the company's preparation for this eventuality, however, the market hasn't been kind to AbbVie's stock during the opening months of 2023. 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. AbbVie Developing a blockbuster medication (a drug with gr... | AbbVie Developing a blockbuster medication (a drug with greater than $1 billion in annual sales) requires a tremendous amount of talent, hard work, cash, and flat-out luck across every single layer of the pharma value chain (preclinical studies, human trials, regulatory affairs, and marketing). AbbVie (NYSE: ABBV) is g... |
22,757 | 2023-02-27 00:00:00 UTC | Notable Monday Option Activity: WSO, ABBV, BMRN | ABBV | https://www.nasdaq.com/articles/notable-monday-option-activity%3A-wso-abbv-bmrn | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Watsco Inc. (Symbol: WSO), where a total of 1,567 contracts have traded so far, representing approximately 156,700 underlying shares. That amounts to about 43.1% of WSO's average daily trading volume over the pa... | Particularly high volume was seen for the $155 strike call option expiring March 03, 2023, with 2,803 contracts trading so far today, representing approximately 280,300 underlying shares of ABBV. Below is a chart showing WSO's trailing twelve month trading history, with the $270 strike highlighted in orange: AbbVie Inc... | Below is a chart showing WSO's trailing twelve month trading history, with the $270 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,124 contracts, representing approximately 2.5 million underlying shares or approximately 41.9% of ABBV's average daily trading volume over the past... | Below is a chart showing WSO's trailing twelve month trading history, with the $270 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,124 contracts, representing approximately 2.5 million underlying shares or approximately 41.9% of ABBV's average daily trading volume over the past... | Below is a chart showing WSO's trailing twelve month trading history, with the $270 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,124 contracts, representing approximately 2.5 million underlying shares or approximately 41.9% of ABBV's average daily trading volume over the past... |
22,758 | 2023-02-27 00:00:00 UTC | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-attracting-investor-attention%3A-here-is-what-you-should-know-5 | null | null | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this drugmaker have returned +4.4%, compared to the Zacks S&P 500 composite's -1% change. Durin... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry... | Last Reported Results and Surprise History AbbVie reported revenues of $15.12 billion in the last reported quarter, representing a year-over-year change of +1.6%. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie ... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which ... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which ... |
22,759 | 2023-02-27 00:00:00 UTC | 3 High-Yield Dividend Stocks to Buy and Hold Forever | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-to-buy-and-hold-forever | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
High-yield dividend stocks offer relatively high dividend yields compared to the average dividend stock. Generally, I view a high-yield dividend to be above the 4-5% range. Investors can calculate a dividend yield by taking the dividend distribution of a co... | ABBV AbbVie $152.71 BIP Brookfield Renewable Partners $34.16 CCI Crown Castle $131.16 AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com First on this list of high-yield dividend stocks is AbbVie (NYSE:ABBV). AbbVie is a pharmaceutical giant that focuses on the development and commercialization of therapeutics... | ABBV AbbVie $152.71 BIP Brookfield Renewable Partners $34.16 CCI Crown Castle $131.16 AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com First on this list of high-yield dividend stocks is AbbVie (NYSE:ABBV). AbbVie is a pharmaceutical giant that focuses on the development and commercialization of therapeutics... | ABBV AbbVie $152.71 BIP Brookfield Renewable Partners $34.16 CCI Crown Castle $131.16 AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com First on this list of high-yield dividend stocks is AbbVie (NYSE:ABBV). AbbVie is a pharmaceutical giant that focuses on the development and commercialization of therapeutics... | ABBV AbbVie $152.71 BIP Brookfield Renewable Partners $34.16 CCI Crown Castle $131.16 AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com First on this list of high-yield dividend stocks is AbbVie (NYSE:ABBV). AbbVie is a pharmaceutical giant that focuses on the development and commercialization of therapeutics... |
22,760 | 2023-02-27 00:00:00 UTC | Merck Stock Looks Better Priced Compared To Its Sector Peer | ABBV | https://www.nasdaq.com/articles/merck-stock-looks-better-priced-compared-to-its-sector-peer | null | null | We believe that Merck stock (NYSE: MRK) is currently a better pick than its peer Eli Lilly stock (NYSE: LLY), given its comparatively lower valuation of 4.7x trailing revenues vs. 10.5x for Eli Lilly. Although investors have assigned a higher P/S multiple for LLY stock owing to its pipeline potential, we believe this g... | We compare a slew of factors, such as historical revenue growth, returns, and profitability, in an interactive dashboard analysis of Merck vs. Eli Lilly: Which Stock Is A Better Bet? Eli Lilly has a robust product cycle, including Alzheimer’s treatment – Donanemab – one of the most anticipated drugs with peak sales peg... | We believe that Merck stock (NYSE: MRK) is currently a better pick than its peer Eli Lilly stock (NYSE: LLY), given its comparatively lower valuation of 4.7x trailing revenues vs. 10.5x for Eli Lilly. Our Merck Operating Income Comparison and Eli Lilly Operating Income Comparison dashboards have more details. Our Merck... | We believe that Merck stock (NYSE: MRK) is currently a better pick than its peer Eli Lilly stock (NYSE: LLY), given its comparatively lower valuation of 4.7x trailing revenues vs. 10.5x for Eli Lilly. If we look at a longer time frame, Eli Lilly has fared slightly better, with its sales rising at an average annual grow... | Merck’s revenue growth has been comparable with Eli Lilly over the recent years, and it is more profitable, as discussed below. There is more to the comparison, and in the sections below, we discuss why we believe MRK stock will offer better returns than LLY stock in the next three years. Still, Merck’s revenue growth ... |
22,761 | 2023-02-27 00:00:00 UTC | AbbVie Gets Positive CHMP Opinion For Upadacitinib For Treatment Of Adults With Crohn's Disease | ABBV | https://www.nasdaq.com/articles/abbvie-gets-positive-chmp-opinion-for-upadacitinib-for-treatment-of-adults-with-crohns | null | null | (RTTNews) - AbbVie (ABBV) said Monday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (Rinvoq) for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost respon... | (RTTNews) - AbbVie (ABBV) said Monday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (Rinvoq) for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost respon... | (RTTNews) - AbbVie (ABBV) said Monday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (Rinvoq) for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost respon... | (RTTNews) - AbbVie (ABBV) said Monday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (Rinvoq) for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost respon... | (RTTNews) - AbbVie (ABBV) said Monday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (Rinvoq) for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost respon... |
22,762 | 2023-02-25 00:00:00 UTC | 3 Biotech Stocks To Watch Ahead Of March 2023 | ABBV | https://www.nasdaq.com/articles/3-biotech-stocks-to-watch-ahead-of-march-2023 | null | null | Biotech stocks represent shares of companies that specialize in the development and commercialization of drugs, therapies, and other medical products based on biological and chemical research. Biotech companies often focus on treating diseases that currently have no cure. Such as cancer, rare genetic disorders, and neu... | Biotech Stocks To Buy [Or Avoid] Now Merck & Company Inc. (NYSE: MRK) AbbVie Inc. (NYSE: ABBV) Biogen Inc. (NASDAQ: BIIB) Merck & Company (MRK Stock) Starting off, Merck & Company Inc. (MRK) is a global pharmaceutical company that develops and sells a wide range of drugs and vaccines across multiple therapeutic areas, ... | Biotech Stocks To Buy [Or Avoid] Now Merck & Company Inc. (NYSE: MRK) AbbVie Inc. (NYSE: ABBV) Biogen Inc. (NASDAQ: BIIB) Merck & Company (MRK Stock) Starting off, Merck & Company Inc. (MRK) is a global pharmaceutical company that develops and sells a wide range of drugs and vaccines across multiple therapeutic areas, ... | Biotech Stocks To Buy [Or Avoid] Now Merck & Company Inc. (NYSE: MRK) AbbVie Inc. (NYSE: ABBV) Biogen Inc. (NASDAQ: BIIB) Merck & Company (MRK Stock) Starting off, Merck & Company Inc. (MRK) is a global pharmaceutical company that develops and sells a wide range of drugs and vaccines across multiple therapeutic areas, ... | Biotech Stocks To Buy [Or Avoid] Now Merck & Company Inc. (NYSE: MRK) AbbVie Inc. (NYSE: ABBV) Biogen Inc. (NASDAQ: BIIB) Merck & Company (MRK Stock) Starting off, Merck & Company Inc. (MRK) is a global pharmaceutical company that develops and sells a wide range of drugs and vaccines across multiple therapeutic areas, ... |
22,763 | 2023-02-25 00:00:00 UTC | Validea Guru Fundamental Report for ABBV - 2/25/2023 | ABBV | https://www.nasdaq.com/articles/validea-guru-fundamental-report-for-abbv-2-25-2023 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis Partha Mohanram Portfolio About P... |
22,764 | 2023-02-24 00:00:00 UTC | IWB, ABBV, PEP, PFE: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/iwb-abbv-pep-pfe%3A-large-outflows-detected-at-etf | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $210.4 million dollar outflow -- that's a 0.7% decrease week over week (from 127,200,000 to 126,250,000). Among t... | Among the largest underlying components of IWB, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.3%, PepsiCo Inc (Symbol: PEP) is down about 0.9%, and Pfizer Inc (Symbol: PFE) is lower by about 1.9%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommo... | Among the largest underlying components of IWB, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.3%, PepsiCo Inc (Symbol: PEP) is down about 0.9%, and Pfizer Inc (Symbol: PFE) is lower by about 1.9%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price perfor... | Among the largest underlying components of IWB, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.3%, PepsiCo Inc (Symbol: PEP) is down about 0.9%, and Pfizer Inc (Symbol: PFE) is lower by about 1.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, ... | Among the largest underlying components of IWB, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.3%, PepsiCo Inc (Symbol: PEP) is down about 0.9%, and Pfizer Inc (Symbol: PFE) is lower by about 1.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, ... |
22,765 | 2023-02-22 00:00:00 UTC | Validea Guru Fundamental Report for ABBV - 2/22/2023 | ABBV | https://www.nasdaq.com/articles/validea-guru-fundamental-report-for-abbv-2-22-2023 | null | null | Below is Validea's daily guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with susta... | Below is Validea's daily guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come... | Below is Validea's daily guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis Partha Mohanram Portfolio A... |
22,766 | 2023-02-22 00:00:00 UTC | Want to Get to $1 Million by Retirement? Here's How Much You Should Invest Today. | ABBV | https://www.nasdaq.com/articles/want-to-get-to-%241-million-by-retirement-heres-how-much-you-should-invest-today. | null | null | When you're in your 20s, you might think you don't have enough money to start putting away for retirement, whereas when you're in your 40s or 50s, you might worry that it's too late to start. In a perfect world, you would start putting money aside as early as you can.
But it doesn't always have to be that way, and even... | But AbbVie has a strong pipeline and is confident that it can more than replace the lost revenue in the long run with the promising immunology drugs Skyrizi and Rinvoq. When it comes to low-risk investments, two great examples are Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV). AbbVie is another highly profitabl... | When it comes to low-risk investments, two great examples are Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV). Investing in stocks like AbbVie and Johnson & Johnson can put you in a good position to earn an average total return of 11% per year. AbbVie is another highly profitable business to invest in. | Investing in stocks like AbbVie and Johnson & Johnson can put you in a good position to earn an average total return of 11% per year. When it comes to low-risk investments, two great examples are Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV). AbbVie is another highly profitable business to invest in. | Investing in stocks like AbbVie and Johnson & Johnson can put you in a good position to earn an average total return of 11% per year. When it comes to low-risk investments, two great examples are Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV). AbbVie is another highly profitable business to invest in. |
22,767 | 2023-02-22 00:00:00 UTC | Analyst Confidence in Eli Lilly Boosted by Product Pipeline | ABBV | https://www.nasdaq.com/articles/analyst-confidence-in-eli-lilly-boosted-by-product-pipeline | null | null | Eli Lilly and Company (NYSE: LLY) is one of the most recognized names in the pharmaceutical industry. Indeed, they are the 12th-largest pharmaceutical company in the world by revenue ($5.5 billion in 2021), and its balance sheet reads as such. But even though LLY has long been a good healthcare stock to hold, analysts ... | Sales forecast for lebrikizumab could reach $990 million by 2026, and while this still trails behind Dupixent and Rinvoq from AbbVie, Inc. (ABBV), Lilly hopes phase 3 trials demonstrate better patient tolerance. But even though LLY has long been a good healthcare stock to hold, analysts anticipate Eli Lilly’s product p... | Sales forecast for lebrikizumab could reach $990 million by 2026, and while this still trails behind Dupixent and Rinvoq from AbbVie, Inc. (ABBV), Lilly hopes phase 3 trials demonstrate better patient tolerance. But even though LLY has long been a good healthcare stock to hold, analysts anticipate Eli Lilly’s product p... | Sales forecast for lebrikizumab could reach $990 million by 2026, and while this still trails behind Dupixent and Rinvoq from AbbVie, Inc. (ABBV), Lilly hopes phase 3 trials demonstrate better patient tolerance. Product Pipeline Could Accelerate Broad Growth On the other hand, Eli Lilly failed to get accelerated approv... | Sales forecast for lebrikizumab could reach $990 million by 2026, and while this still trails behind Dupixent and Rinvoq from AbbVie, Inc. (ABBV), Lilly hopes phase 3 trials demonstrate better patient tolerance. Stable Earnings Strengthens Opportunities With $314.15 billion in market capitalization, the US-based multin... |
22,768 | 2023-02-22 00:00:00 UTC | This Recession-Proof Company Has a Best-in-Class Dividend | ABBV | https://www.nasdaq.com/articles/this-recession-proof-company-has-a-best-in-class-dividend | null | null | Pharmaceutical companies have a recession-proof business model. The simple reason behind this fact is that people do not choose when they get sick. So, for example, the pharmaceutical industry was largely unaffected by the devastating 2008 global recession. In fact, earnings per share among the industry's biggest names... | So here is a quantitative breakdown of the most recent stock valuations and dividend programs of AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), Gilead Sciences (NASDAQ: GILD), Pfizer (NYSE: PFE), and Merck (NYSE: MRK). AbbVie 13.2 4.58 ... | So here is a quantitative breakdown of the most recent stock valuations and dividend programs of AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), Gilead Sciences (NASDAQ: GILD), Pfizer (NYSE: PFE), and Merck (NYSE: MRK). AbbVie 13.2 4.58 ... | So here is a quantitative breakdown of the most recent stock valuations and dividend programs of AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), Gilead Sciences (NASDAQ: GILD), Pfizer (NYSE: PFE), and Merck (NYSE: MRK). AbbVie 13.2 4.58 ... | So here is a quantitative breakdown of the most recent stock valuations and dividend programs of AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), Gilead Sciences (NASDAQ: GILD), Pfizer (NYSE: PFE), and Merck (NYSE: MRK). AbbVie 13.2 4.58 ... |
22,769 | 2023-02-22 00:00:00 UTC | Want More Reliable Dividend Income? Buy This Dividend King. | ABBV | https://www.nasdaq.com/articles/want-more-reliable-dividend-income-buy-this-dividend-king. | null | null | The pharmaceutical industry is ripe for the picking for income investors. That's because the industry enjoys particularly high profit margins, which can fund generous dividends. But as is the case with anything good, there are still risks.
In pharmaceuticals, the biggest risk is the patent expiration of top-performing ... | Net revenue and earnings keep moving higher With products marketed in more than 175 countries and treating over 62 million patients each year, AbbVie is one of the most impactful drugmakers on the planet. Careful cost management (operating expenses declined 2%) helped AbbVie's non-GAAP net margin expand by 540 basis po... | This solid net revenue growth was fueled by AbbVie's stacked drug portfolio, which included Humira and Skyrizi, two mega-blockbuster drugs (at least $5 billion in annualized net revenue). While this will lead to billions in lost annual revenue for the drug franchise this year and beyond, Skyrizi along with AbbVie's oth... | This solid net revenue growth was fueled by AbbVie's stacked drug portfolio, which included Humira and Skyrizi, two mega-blockbuster drugs (at least $5 billion in annualized net revenue). While this will lead to billions in lost annual revenue for the drug franchise this year and beyond, Skyrizi along with AbbVie's oth... | This solid net revenue growth was fueled by AbbVie's stacked drug portfolio, which included Humira and Skyrizi, two mega-blockbuster drugs (at least $5 billion in annualized net revenue). While this will lead to billions in lost annual revenue for the drug franchise this year and beyond, Skyrizi along with AbbVie's oth... |
22,770 | 2023-02-21 00:00:00 UTC | Johnson & Johnson: Taking The Bull By The Horns? | ABBV | https://www.nasdaq.com/articles/johnson-johnson%3A-taking-the-bull-by-the-horns | null | null | Johnson & Johnson (NYSE: JNJ) recently filed a shelf registration with the SEC, suggesting it is preparing for the future. The filing is for debt securities, not shares, to be sold on an ongoing basis at a future date that could be as soon as the filing was received. The offering aims to raise capital for general corpo... | A Patent Cliff Is Approaching For Pharma Companies Fitch outlines how companies from AstraZeneca (NYSE: AZN) to AbbVie (NYSE: ABBV), already facing patent-related pressure, are approaching a patent cliff and Johnson & Johnson is not immune. A patent cliff is when patents on blockbuster drugs like AbbVie’s Humira expire... | A Patent Cliff Is Approaching For Pharma Companies Fitch outlines how companies from AstraZeneca (NYSE: AZN) to AbbVie (NYSE: ABBV), already facing patent-related pressure, are approaching a patent cliff and Johnson & Johnson is not immune. A patent cliff is when patents on blockbuster drugs like AbbVie’s Humira expire... | A Patent Cliff Is Approaching For Pharma Companies Fitch outlines how companies from AstraZeneca (NYSE: AZN) to AbbVie (NYSE: ABBV), already facing patent-related pressure, are approaching a patent cliff and Johnson & Johnson is not immune. A patent cliff is when patents on blockbuster drugs like AbbVie’s Humira expire... | A Patent Cliff Is Approaching For Pharma Companies Fitch outlines how companies from AstraZeneca (NYSE: AZN) to AbbVie (NYSE: ABBV), already facing patent-related pressure, are approaching a patent cliff and Johnson & Johnson is not immune. A patent cliff is when patents on blockbuster drugs like AbbVie’s Humira expire... |
22,771 | 2023-02-20 00:00:00 UTC | 3 Top Dividend Kings to Buy for the Long Haul | ABBV | https://www.nasdaq.com/articles/3-top-dividend-kings-to-buy-for-the-long-haul-6 | null | null | For long-term investors, there are not many things better than finding a profitable company paying you to hold shares. Yes, I'm talking about dividends. The best companies can give you annual raises, which can add to substantial investment returns over time. If a company in the S&P 500 can pay and raise its dividend an... | AbbVie Pharmaceutical company AbbVie (NYSE: ABBV) has grown by leaps and bounds since splitting from Abbott a decade ago. AbbVie is known for its best-selling drug Humira, the Botox brand, and several others that add up to $58 billion in annual sales. AbbVie has continued its dividend-growing tradition, now at a 51-yea... | ABBV Revenue (TTM) data by YCharts However, growth could slow in the years ahead; analysts are looking for EPS growth averaging 4% annually over the next few years. AbbVie Pharmaceutical company AbbVie (NYSE: ABBV) has grown by leaps and bounds since splitting from Abbott a decade ago. AbbVie is known for its best-sell... | AbbVie Pharmaceutical company AbbVie (NYSE: ABBV) has grown by leaps and bounds since splitting from Abbott a decade ago. AbbVie is known for its best-selling drug Humira, the Botox brand, and several others that add up to $58 billion in annual sales. AbbVie has continued its dividend-growing tradition, now at a 51-yea... | AbbVie Pharmaceutical company AbbVie (NYSE: ABBV) has grown by leaps and bounds since splitting from Abbott a decade ago. AbbVie is known for its best-selling drug Humira, the Botox brand, and several others that add up to $58 billion in annual sales. AbbVie has continued its dividend-growing tradition, now at a 51-yea... |
22,772 | 2023-02-19 00:00:00 UTC | Validea's Top Ten Healthcare Stocks Based On David Dreman - 2/19/2023 | ABBV | https://www.nasdaq.com/articles/valideas-top-ten-healthcare-stocks-based-on-david-dreman-2-19-2023 | null | null | The following are the top rated Healthcare stocks according to Validea's Contrarian Investor model based on the published strategy of David Dreman. This contrarian strategy finds the most unpopular mid- and large-cap stocks in the market and looks for improving fundamentals.
BIONTECH SE - ADR (BNTX) is a large-cap valu... | Detailed Analysis of VIR BIOTECHNOLOGY INC VIR Guru Analysis VIR Fundamental Analysis ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. is a research-based biopharmaceutical company, which is engaged in research and development, manufacturing, commerci... | Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis EDWARDS LIFESCIENCES CORP (EW) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of VIR BIOTECHNOLOGY INC VIR Guru Analysis VIR Fundamental Analysis ABBVIE INC (ABBV) is a large-cap growth stock in the... | Detailed Analysis of VIR BIOTECHNOLOGY INC VIR Guru Analysis VIR Fundamental Analysis ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. is a research-based biopharmaceutical company, which is engaged in research and development, manufacturing, commerci... | Detailed Analysis of VIR BIOTECHNOLOGY INC VIR Guru Analysis VIR Fundamental Analysis ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. is a research-based biopharmaceutical company, which is engaged in research and development, manufacturing, commerci... |
22,773 | 2023-02-18 00:00:00 UTC | 3 Dividend Stocks That Should Pay You the Rest of Your Life | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-that-should-pay-you-the-rest-of-your-life-2 | null | null | Building a portfolio for passive income can be a challenging process, especially if you are just starting out. But it doesn't have to be this way. Investors simply need to buy at least a couple of dozen proven dividend payers across a variety of economic sectors to build a durable portfolio.
Whether you're new to incom... | AbbVie: An innovative pharmaceutical company AbbVie's (NYSE: ABBV) $264 billion market cap earns it the distinction of being the fourth-biggest pharmaceutical company on the planet. In 2022, 13 of AbbVie's drug franchises were blockbusters (i.e., they recorded at least $1 billion in sales). With such an impressive prod... | AbbVie: An innovative pharmaceutical company AbbVie's (NYSE: ABBV) $264 billion market cap earns it the distinction of being the fourth-biggest pharmaceutical company on the planet. In 2022, 13 of AbbVie's drug franchises were blockbusters (i.e., they recorded at least $1 billion in sales). With such an impressive prod... | See the 10 stocks *Stock Advisor returns as of February 8, 2023 Kody Kester has positions in AbbVie, Procter & Gamble, and Realty Income. AbbVie: An innovative pharmaceutical company AbbVie's (NYSE: ABBV) $264 billion market cap earns it the distinction of being the fourth-biggest pharmaceutical company on the planet. ... | That should allow AbbVie's 51-year streak of dividend growth to continue in the years ahead. AbbVie: An innovative pharmaceutical company AbbVie's (NYSE: ABBV) $264 billion market cap earns it the distinction of being the fourth-biggest pharmaceutical company on the planet. In 2022, 13 of AbbVie's drug franchises were ... |
22,774 | 2023-02-17 00:00:00 UTC | Daily Dividend Report: NEE,KO,FDX,K,ABBV | ABBV | https://www.nasdaq.com/articles/daily-dividend-report%3A-neekofdxkabbv | null | null | The board of directors of NextEra Energy declared a regular quarterly common stock dividend of $0.4675 per share, an approximate 10% increase versus the prior-year comparable quarterly dividend. This increase is consistent with the plan announced in 2022 of targeting roughly 10% annual growth in dividends per share thr... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.48 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 270 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.48 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 270 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.48 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 270 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.48 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 270 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... |
22,775 | 2023-02-17 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-with-upside-to-analyst-targets-69 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | AbbVie Inc (Symbol: ABBV) $149.53 $165.28 10.54% RenaissanceRe Holdings Ltd. (Symbol: RNR) $210.76 $229.50 8.89% Nordson Corp. (Symbol: NDSN) $242.48 $263.17 8.53% National Retail Properties Inc (Symbol: NNN) $46.77 $50.33 7.62% SJW Group (Symbol: SJW) $76.18 $81.67 7.20% The average 12-month analyst targets are only t... | AbbVie Inc (Symbol: ABBV) $149.53 $165.28 10.54% RenaissanceRe Holdings Ltd. (Symbol: RNR) $210.76 $229.50 8.89% Nordson Corp. (Symbol: NDSN) $242.48 $263.17 8.53% National Retail Properties Inc (Symbol: NNN) $46.77 $50.33 7.62% SJW Group (Symbol: SJW) $76.18 $81.67 7.20% The average 12-month analyst targets are only t... | AbbVie Inc (Symbol: ABBV) $149.53 $165.28 10.54% RenaissanceRe Holdings Ltd. (Symbol: RNR) $210.76 $229.50 8.89% Nordson Corp. (Symbol: NDSN) $242.48 $263.17 8.53% National Retail Properties Inc (Symbol: NNN) $46.77 $50.33 7.62% SJW Group (Symbol: SJW) $76.18 $81.67 7.20% The average 12-month analyst targets are only t... | AbbVie Inc (Symbol: ABBV) $149.53 $165.28 10.54% RenaissanceRe Holdings Ltd. (Symbol: RNR) $210.76 $229.50 8.89% Nordson Corp. (Symbol: NDSN) $242.48 $263.17 8.53% National Retail Properties Inc (Symbol: NNN) $46.77 $50.33 7.62% SJW Group (Symbol: SJW) $76.18 $81.67 7.20% The average 12-month analyst targets are only t... |
22,776 | 2023-02-17 00:00:00 UTC | 3 Exceptional Dividend Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-exceptional-dividend-stocks-to-buy-right-now | null | null | What makes a good dividend stock? One important element is dividend growth.
A company that has lifted its payout year after year is one you may want to have in your portfolio. That's because it's shown its commitment to rewarding shareholders. And that means it's likely to continue along those lines.
The best place to ... | The good news is AbbVie's newer immunology drugs, Rinvoq and Skyrizi, are set to surpass Humira's peak of more than $20 billion in annual revenue. AbbVie AbbVie (NYSE: ABBV) has increased its dividend by 270% since its inception. If you held AbbVie over the past five years, your total return -- that's the gain includin... | If you held AbbVie over the past five years, your total return -- that's the gain including dividends -- would have been more than double AbbVie's share-price performance during that time period. AbbVie AbbVie (NYSE: ABBV) has increased its dividend by 270% since its inception. So dividends clearly are a compelling par... | If you held AbbVie over the past five years, your total return -- that's the gain including dividends -- would have been more than double AbbVie's share-price performance during that time period. AbbVie AbbVie (NYSE: ABBV) has increased its dividend by 270% since its inception. So dividends clearly are a compelling par... | AbbVie AbbVie (NYSE: ABBV) has increased its dividend by 270% since its inception. If you held AbbVie over the past five years, your total return -- that's the gain including dividends -- would have been more than double AbbVie's share-price performance during that time period. So dividends clearly are a compelling par... |
22,777 | 2023-02-17 00:00:00 UTC | Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases | ABBV | https://www.nasdaq.com/articles/ironwood-irwd-q4-earnings-miss-linzess-volume-increases | null | null | Ironwood Pharmaceuticals, Inc. IRWD reported adjusted earnings of 27 cents per share in fourth-quarter 2022, missing both the Zacks Consensus Estimate and our estimate of 28 cents and 29 cents per share, respectively. The reported earnings were in line with the year-ago quarter figure.
Total revenues of $107.2 million ... | Earlier this week, the company, along with partner AbbVie, announced that the FDA accepted and granted priority review to a supplemental new drug application (sNDA), seeking expanded use of Linzess for children and adolescents with functional constipation (“FC”). Image Source: Zacks Investment Research Quarter in Detai... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $260.3 million in the United States, down 7% year over year. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Re... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $260.3 million in the United States, down 7% year over year. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Re... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $260.3 million in the United States, down 7% year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or lo... |
22,778 | 2023-02-17 00:00:00 UTC | 2 Exceptional Growth Stocks to Buy Before the Next Bull Market | ABBV | https://www.nasdaq.com/articles/2-exceptional-growth-stocks-to-buy-before-the-next-bull-market | null | null | No matter how tough it can be to hold onto your investments when they are losing value during bear markets, they always end, and bull markets are liable to kick off shortly thereafter. In fact, investors who keep buying shares of quality companies when the mood on Wall Street is sour are the ones who tend to get a lot ... | AbbVie The reason AbbVie (NYSE: ABBV) is worth purchasing before the next bull market is that its valuation is a decent bargain relative to other businesses in the pharmaceutical industry. That means you should get a bit more bang for your buck with AbbVie's shares than with shares of one of its competitors. And there'... | AbbVie The reason AbbVie (NYSE: ABBV) is worth purchasing before the next bull market is that its valuation is a decent bargain relative to other businesses in the pharmaceutical industry. That means you should get a bit more bang for your buck with AbbVie's shares than with shares of one of its competitors. And there'... | AbbVie The reason AbbVie (NYSE: ABBV) is worth purchasing before the next bull market is that its valuation is a decent bargain relative to other businesses in the pharmaceutical industry. That means you should get a bit more bang for your buck with AbbVie's shares than with shares of one of its competitors. And there'... | AbbVie The reason AbbVie (NYSE: ABBV) is worth purchasing before the next bull market is that its valuation is a decent bargain relative to other businesses in the pharmaceutical industry. That means you should get a bit more bang for your buck with AbbVie's shares than with shares of one of its competitors. And there'... |
22,779 | 2023-02-16 00:00:00 UTC | Noteworthy Thursday Option Activity: LMT, MGM, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-lmt-mgm-abbv | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Lockheed Martin Corp (Symbol: LMT), where a total of 8,810 contracts have traded so far, representing approximately 881,000 underlying shares. That amounts to about 57.2% of LMT's average daily trading volume over th... | Especially high volume was seen for the $160 strike call option expiring March 17, 2023, with 17,479 contracts trading so far today, representing approximately 1.7 million underlying shares of ABBV. Below is a chart showing MGM's trailing twelve month trading history, with the $15 strike highlighted in orange: And AbbV... | Below is a chart showing MGM's trailing twelve month trading history, with the $15 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 31,294 contracts thus far today. Especially high volume was seen for the $160 strike call option expiring March 17, 2023, with 17,479 contracts t... | Especially high volume was seen for the $160 strike call option expiring March 17, 2023, with 17,479 contracts trading so far today, representing approximately 1.7 million underlying shares of ABBV. Below is a chart showing MGM's trailing twelve month trading history, with the $15 strike highlighted in orange: And AbbV... | Especially high volume was seen for the $160 strike call option expiring March 17, 2023, with 17,479 contracts trading so far today, representing approximately 1.7 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $160 strike highlighted in orange: For th... |
22,780 | 2023-02-16 00:00:00 UTC | iShares Core S&P U.S. Growth ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-core-sp-u.s.-growth-etf-experiences-big-inflow-0 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $105.9 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 136,450... | Among the largest underlying components of IUSG, in trading today Merck & Co Inc (Symbol: MRK) is down about 0.6%, AbbVie Inc (Symbol: ABBV) is off about 1.1%, and Pfizer Inc (Symbol: PFE) is lower by about 1%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accomm... | Among the largest underlying components of IUSG, in trading today Merck & Co Inc (Symbol: MRK) is down about 0.6%, AbbVie Inc (Symbol: ABBV) is off about 1.1%, and Pfizer Inc (Symbol: PFE) is lower by about 1%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price perf... | Among the largest underlying components of IUSG, in trading today Merck & Co Inc (Symbol: MRK) is down about 0.6%, AbbVie Inc (Symbol: ABBV) is off about 1.1%, and Pfizer Inc (Symbol: PFE) is lower by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... | Among the largest underlying components of IUSG, in trading today Merck & Co Inc (Symbol: MRK) is down about 0.6%, AbbVie Inc (Symbol: ABBV) is off about 1.1%, and Pfizer Inc (Symbol: PFE) is lower by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... |
22,781 | 2023-02-16 00:00:00 UTC | These 2 Growth Stocks Are Easily Defying the Bear Market | ABBV | https://www.nasdaq.com/articles/these-2-growth-stocks-are-easily-defying-the-bear-market | null | null | Even if it isn't a good idea to fixate on how your investments perform on a month-to-month basis, it's always a plus when your stocks can shrug off the detrimental impact of a bear market. And with the market falling back sharply during the past 12 months amid rising economic instability, that's no idle concern right n... | Nonetheless, AbbVie's shares are powering along as always, with their total return increasing by more than 12.4% since mid-February of 2022 -- unusually strong performance for a company that's anticipated to make less money in the near future than it does today. AbbVie Wall Street analysts are estimating that AbbVie's ... | AbbVie Wall Street analysts are estimating that AbbVie's (NYSE: ABBV) revenue will contract both this year and next year owing to generic competition to its hit medicine, Humira. Nonetheless, AbbVie's shares are powering along as always, with their total return increasing by more than 12.4% since mid-February of 2022 -... | One of the reasons for this discrepancy between expectations and the stock's performance is that AbbVie simply isn't very affected by economic headwinds; it develops medicines, and people aren't going to stop getting critical treatment unless their finances are especially dire. AbbVie Wall Street analysts are estimatin... | Nonetheless, AbbVie's shares are powering along as always, with their total return increasing by more than 12.4% since mid-February of 2022 -- unusually strong performance for a company that's anticipated to make less money in the near future than it does today. And AbbVie has plenty of chances to commercialize new med... |
22,782 | 2023-02-16 00:00:00 UTC | Is This the Start of a Nightmare for AbbVie Stock? | ABBV | https://www.nasdaq.com/articles/is-this-the-start-of-a-nightmare-for-abbvie-stock | null | null | With a small army of Wall Street analysts predicting on average that AbbVie's (NYSE: ABBV) revenue will shrink in 2023 as well as in 2024, investors are right to be cautious, and perhaps even a bit skittish. At the same time, the total return of the biopharma's shares is up by 12.4% in the last 12 months, handily beati... | With a small army of Wall Street analysts predicting on average that AbbVie's (NYSE: ABBV) revenue will shrink in 2023 as well as in 2024, investors are right to be cautious, and perhaps even a bit skittish. Let's answer those two questions by examining why people might be rightfully bearish about AbbVie's prospects ov... | On Jan. 31, Amgen launched its drug Amjevita, a biosimilar copy of AbbVie's hit drug Humira, in the U.S. Like Humira, Amjevita is intended to treat a smattering of immunological conditions that affect millions of people, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and psoriasis. With a smal... | On Jan. 31, Amgen launched its drug Amjevita, a biosimilar copy of AbbVie's hit drug Humira, in the U.S. Like Humira, Amjevita is intended to treat a smattering of immunological conditions that affect millions of people, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and psoriasis. 10 stocks w... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! With a small army of Wall Street analysts predicting on average that AbbVie's (NYSE: ABBV) revenue will shrink in 2023 as well as in 2024, investors are right to be cautious, and perhaps even ... |
22,783 | 2023-02-16 00:00:00 UTC | Validea Daily Guru Fundamental Report for ABBV - 2/16/2023 | ABBV | https://www.nasdaq.com/articles/validea-daily-guru-fundamental-report-for-abbv-2-16-2023 | null | null | Below is Validea's daily guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. This multi-factor model seeks low volatility stocks that also have strong momentum and high net payout y... | Below is Validea's daily guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis Pim van Vliet Portfolio About Pim van Vliet: In investing, you typically need to take more risk to ... | Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis Pim van Vliet Portfolio About Pim van Vliet: In investing, you typically need to take more risk to ... | Below is Validea's daily guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis Pim van Vliet Portfolio Abo... |
22,784 | 2023-02-15 00:00:00 UTC | 3 Defensive Growth Stocks to Load Up on in Q1 | ABBV | https://www.nasdaq.com/articles/3-defensive-growth-stocks-to-load-up-on-in-q1 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In this rather uncertain market, the search for defensive growth stocks is picking up. Indeed, this category of high-quality companies with steady cash flows and growing dividend distributions are sought out in times of turmoil. With interest rates on the r... | While I cannot predict whether AbbVie will beat the market in 2023, the stock will be lucrative for investors in the long run due to its strong dividend and its impressive pipeline. MCD McDonald’s $266.16 ABBV AbbVie $151.80 NOC Northrop Grumman $461.81 McDonald’s (MCD) Source: 8th.creator / Shutterstock.com We all lov... | MCD McDonald’s $266.16 ABBV AbbVie $151.80 NOC Northrop Grumman $461.81 McDonald’s (MCD) Source: 8th.creator / Shutterstock.com We all love a classic, and McDonald’s (NYSE:MCD) is no exception. AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie (NYSE:ABBV) is a healthcare stock that’s rated BBB+ by S&P,... | MCD McDonald’s $266.16 ABBV AbbVie $151.80 NOC Northrop Grumman $461.81 McDonald’s (MCD) Source: 8th.creator / Shutterstock.com We all love a classic, and McDonald’s (NYSE:MCD) is no exception. AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie (NYSE:ABBV) is a healthcare stock that’s rated BBB+ by S&P,... | MCD McDonald’s $266.16 ABBV AbbVie $151.80 NOC Northrop Grumman $461.81 McDonald’s (MCD) Source: 8th.creator / Shutterstock.com We all love a classic, and McDonald’s (NYSE:MCD) is no exception. AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com AbbVie (NYSE:ABBV) is a healthcare stock that’s rated BBB+ by S&P,... |
22,785 | 2023-02-15 00:00:00 UTC | Bausch + Lomb to name Brent Saunders as CEO - WSJ | ABBV | https://www.nasdaq.com/articles/bausch-lomb-to-name-brent-saunders-as-ceo-wsj-0 | null | null | Adds background on Brent Saunders
Feb 15 (Reuters) - Eye-care company Bausch + Lomb Corp BLCO.TO is expected to name Brent Saunders, the former chief executive of Allergan, as its CEO and chairman of board, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
The leadership change coul... | Brent Saunders served as the CEO of Allergan until it was bought out by AbbVie Inc ABBV.N for $63 billion in 2020. Adds background on Brent Saunders Feb 15 (Reuters) - Eye-care company Bausch + Lomb Corp BLCO.TO is expected to name Brent Saunders, the former chief executive of Allergan, as its CEO and chairman of board... | Brent Saunders served as the CEO of Allergan until it was bought out by AbbVie Inc ABBV.N for $63 billion in 2020. Adds background on Brent Saunders Feb 15 (Reuters) - Eye-care company Bausch + Lomb Corp BLCO.TO is expected to name Brent Saunders, the former chief executive of Allergan, as its CEO and chairman of board... | Brent Saunders served as the CEO of Allergan until it was bought out by AbbVie Inc ABBV.N for $63 billion in 2020. Adds background on Brent Saunders Feb 15 (Reuters) - Eye-care company Bausch + Lomb Corp BLCO.TO is expected to name Brent Saunders, the former chief executive of Allergan, as its CEO and chairman of board... | Brent Saunders served as the CEO of Allergan until it was bought out by AbbVie Inc ABBV.N for $63 billion in 2020. Adds background on Brent Saunders Feb 15 (Reuters) - Eye-care company Bausch + Lomb Corp BLCO.TO is expected to name Brent Saunders, the former chief executive of Allergan, as its CEO and chairman of board... |
22,786 | 2023-02-14 00:00:00 UTC | 2 High-Yielding Dividend Stocks Trading Near 52-Week Lows | ABBV | https://www.nasdaq.com/articles/2-high-yielding-dividend-stocks-trading-near-52-week-lows | null | null | A good incentive for buying a strong dividend stock that's underperforming is that you can secure a higher yield. As long as the business's fundamentals remain sound, you can benefit from the better-than-usual payout as well as from the potential capital appreciation it generates if the stock rebounds and rises in valu... | But AbbVie management has said it isn't too concerned, as it believes the combination of two promising immunology drugs, Rinvoq and Skyrizi, can make up for the shortfall in the long haul. Two relatively cheap healthcare stocks offering above-average yields and that are trading near their 52-week lows are Pfizer (NYSE:... | Two relatively cheap healthcare stocks offering above-average yields and that are trading near their 52-week lows are Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV). AbbVie Another stock investors are not enthused about these days is AbbVie. But AbbVie management has said it isn't too concerned, as it believes the combinat... | Two relatively cheap healthcare stocks offering above-average yields and that are trading near their 52-week lows are Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV). AbbVie Another stock investors are not enthused about these days is AbbVie. But AbbVie management has said it isn't too concerned, as it believes the combinat... | Two relatively cheap healthcare stocks offering above-average yields and that are trading near their 52-week lows are Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV). AbbVie Another stock investors are not enthused about these days is AbbVie. But AbbVie management has said it isn't too concerned, as it believes the combinat... |
22,787 | 2023-02-14 00:00:00 UTC | 3 of the BEST Dividend Growth Stocks | ABBV | https://www.nasdaq.com/articles/3-of-the-best-dividend-growth-stocks | null | null | Today, I will discuss three of the best dividend growth stocks to invest in. Not only do all these companies increase their dividends at a fast pace, but they are also high-quality companies. One of those happens to be AbbVie (NYSE: ABBV), which I consider the "Investor's Trifecta."
Check out this short video to learn ... | One of those happens to be AbbVie (NYSE: ABBV), which I consider the "Investor's Trifecta." 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't o... | See the 10 stocks *Stock Advisor returns as of February 8, 2023 Mark Roussin, CPA has positions in AbbVie and Broadcom. One of those happens to be AbbVie (NYSE: ABBV), which I consider the "Investor's Trifecta." 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to list... | 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of February 8, 2023 Mark Roussin, CPA has positions in AbbVie and Broadcom. One of those happens to be AbbVie (NYSE: ABBV), which I consider the "Investor's Trifect... | See the 10 stocks *Stock Advisor returns as of February 8, 2023 Mark Roussin, CPA has positions in AbbVie and Broadcom. One of those happens to be AbbVie (NYSE: ABBV), which I consider the "Investor's Trifecta." 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to list... |
22,788 | 2023-02-14 00:00:00 UTC | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-a-trending-stock%3A-facts-to-know-before-betting-on-it-4 | null | null | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned +0.1% over the past month versus the Zacks S&P 500 composite's +3.6% chan... | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 2.7% over this period. AbbVie is expected to post earnings of $2.58 per share for the current quarter, representing a year-over-year change of -18.4%. | For the next fiscal year, the consensus earnings estimate of $11.02 indicates a change of -1.1% from what AbbVie is expected to report a year ago. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 2.7% over th... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has ... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has ... |
22,789 | 2023-02-14 00:00:00 UTC | Better Buy: Johnson & Johnson or AbbVie? | ABBV | https://www.nasdaq.com/articles/better-buy%3A-johnson-johnson-or-abbvie | null | null | Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) are two of the bigger names in healthcare stocks. The companies are favored by income-oriented investors because each has raised its dividend for 50 years or more.
This is a pivotal year for both. Johnson & Johnson is expected to complete the spinoff of its consumer... | Despite overhanging concerns about how the company will fare now that blockbuster immuno-oncology drug Humira is beginning to face generic competition in the U.S., AbbVie's shares are up more than 7% over the past year. Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) are two of the bigger names in healthcare stoc... | Despite overhanging concerns about how the company will fare now that blockbuster immuno-oncology drug Humira is beginning to face generic competition in the U.S., AbbVie's shares are up more than 7% over the past year. Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) are two of the bigger names in healthcare stoc... | Johnson & Johnson is a little more diversified than AbbVie, even after the expected spinoff, because it is also a pharmaceutical company and a medtech company. Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) are two of the bigger names in healthcare stocks. AbbVie's Humira, for years the world's top-selling drug,... | AbbVie has an even better dividend than Johnson & Johnson. Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) are two of the bigger names in healthcare stocks. AbbVie's Humira, for years the world's top-selling drug, will begin to face generic competition in the U.S. for the first time this year. |
22,790 | 2023-02-14 00:00:00 UTC | Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA | ABBV | https://www.nasdaq.com/articles/ironwood-irwd-gets-fda-priority-tag-for-linzess-snda | null | null | Ironwood Pharmaceuticals IRWD announced that the FDA has accepted and granted priority review to a supplemental new drug application (sNDA), seeking expanded use of Linzess (linaclotide) for children and adolescents with functional constipation (“FC”). The FDA has assigned a PDUFA date of Jun 14, 2023.
Ironwood had fil... | Linzess, developed by Ironwood and its partner AbbVie ABBV, is the sole commercial product in Ironwood’s portfolio. Ironwood and partner AbbVie co-develop and co-commercialize Linzess and equally share Linzess' U.S. collaboration profits or losses as well as all development costs. Linzess is marketed by AbbVie for IBS-... | Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Ironwood Pharmaceuticals, Inc. (IRWD) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report To read this article on Zacks.com click here. Linzess, de... | Ironwood and partner AbbVie co-develop and co-commercialize Linzess and equally share Linzess' U.S. collaboration profits or losses as well as all development costs. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Ironwood Pharmaceuticals, Inc. (IRWD) : Free Stock Analysis Report AbbVie... | Linzess, developed by Ironwood and its partner AbbVie ABBV, is the sole commercial product in Ironwood’s portfolio. Ironwood and partner AbbVie co-develop and co-commercialize Linzess and equally share Linzess' U.S. collaboration profits or losses as well as all development costs. Linzess is marketed by AbbVie for IBS-... |
22,791 | 2023-02-13 00:00:00 UTC | The 7 Most Undervalued Dividend Aristocrats to Buy | ABBV | https://www.nasdaq.com/articles/the-7-most-undervalued-dividend-aristocrats-to-buy | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If there’s anything better than having at least some exposure to passive income-providing enterprises, it’s loading the boat on the most undervalued dividend aristocrats to buy. Per Investopedia, “[d]ividend aristocrats are stocks of companies that have rai... | AFL Aflac $71.01 DOV Dover $155.70 ABBV AbbVie $153.73 PNR Pentair $56.54 GD General Dynamics $232.88 EMR Emerson Electric $86.91 ADM Archer Daniels Midland $81.90 Aflac (AFL) Source: jittawit21/Shutterstock.com An American insurance company, Aflac (NYSE:AFL) specializes in supplemental insurance. AbbVie (ABBV) Source:... | AFL Aflac $71.01 DOV Dover $155.70 ABBV AbbVie $153.73 PNR Pentair $56.54 GD General Dynamics $232.88 EMR Emerson Electric $86.91 ADM Archer Daniels Midland $81.90 Aflac (AFL) Source: jittawit21/Shutterstock.com An American insurance company, Aflac (NYSE:AFL) specializes in supplemental insurance. AbbVie (ABBV) Source:... | AFL Aflac $71.01 DOV Dover $155.70 ABBV AbbVie $153.73 PNR Pentair $56.54 GD General Dynamics $232.88 EMR Emerson Electric $86.91 ADM Archer Daniels Midland $81.90 Aflac (AFL) Source: jittawit21/Shutterstock.com An American insurance company, Aflac (NYSE:AFL) specializes in supplemental insurance. AbbVie (ABBV) Source:... | AFL Aflac $71.01 DOV Dover $155.70 ABBV AbbVie $153.73 PNR Pentair $56.54 GD General Dynamics $232.88 EMR Emerson Electric $86.91 ADM Archer Daniels Midland $81.90 Aflac (AFL) Source: jittawit21/Shutterstock.com An American insurance company, Aflac (NYSE:AFL) specializes in supplemental insurance. AbbVie (ABBV) Source:... |
22,792 | 2023-02-13 00:00:00 UTC | AbbVie Has a Mixed Outlook After Mixed Earnings | ABBV | https://www.nasdaq.com/articles/abbvie-has-a-mixed-outlook-after-mixed-earnings | null | null | AbbVie Inc. (NYSE: ABBV) stock is back to where it started after the day after posting a mixed fourth-quarter earnings report. The company delivered a slight beat on expected earnings but came in light on the top line.
Immediately after the report, ABBV stock gapped up 5.8% in pre-market trading. But investors began ... | AbbVie Inc. (NYSE: ABBV) stock is back to where it started after the day after posting a mixed fourth-quarter earnings report. Wait for a Better Entry Point Before Buying AbbVie Analyst sentiment has been generally bullish since the company’s earnings report. Immediately after the report, ABBV stock gapped up 5.8% in p... | The Good and the Bad About the Company’s Guidance One reason why AbbVie’s stock took a tumble was its earnings guidance for 2023. The pair combined for approximately $2.3 billion in revenue in the last quarter, suggesting that AbbVie is on track to hit that number. Wait for a Better Entry Point Before Buying AbbVie Ana... | The Good and the Bad About the Company’s Guidance One reason why AbbVie’s stock took a tumble was its earnings guidance for 2023. AbbVie Inc. (NYSE: ABBV) stock is back to where it started after the day after posting a mixed fourth-quarter earnings report. Immediately after the report, ABBV stock gapped up 5.8% in pre-... | The Good and the Bad About the Company’s Guidance One reason why AbbVie’s stock took a tumble was its earnings guidance for 2023. AbbVie Inc. (NYSE: ABBV) stock is back to where it started after the day after posting a mixed fourth-quarter earnings report. Immediately after the report, ABBV stock gapped up 5.8% in pre-... |
22,793 | 2023-02-11 00:00:00 UTC | Here's Exactly How AbbVie Stock Can Beat the Market In 2023 | ABBV | https://www.nasdaq.com/articles/heres-exactly-how-abbvie-stock-can-beat-the-market-in-2023 | null | null | AbbVie (NYSE: ABBV) stated this week that its earnings could potentially plunge more than 20% this year. The culprit is no secret: The company's top-selling drug, Humira, now faces biosimilar competition in the U.S.
With this forecast, you might think that AbbVie is destined to perform poorly for a while. However, that... | The culprit is no secret: The company's top-selling drug, Humira, now faces biosimilar competition in the U.S. With this forecast, you might think that AbbVie is destined to perform poorly for a while. Investors shouldn't be overly giddy if AbbVie's first- and second-quarter results show relatively minor sales declines... | Indeed, over the last 10 years, AbbVie's total return was over 520%, while its share price gains during the period were below 320%. AbbVie (NYSE: ABBV) stated this week that its earnings could potentially plunge more than 20% this year. The culprit is no secret: The company's top-selling drug, Humira, now faces biosimi... | Here's exactly how AbbVie stock can beat the market in 2023. Don't forget AbbVie's dividend as a key weapon to help the stock beat the market this year. See the 10 stocks *Stock Advisor returns as of February 8, 2023 Keith Speights has positions in AbbVie. | Here's exactly how AbbVie stock can beat the market in 2023. I don't know whether or not AbbVie will actually beat the market in 2023. AbbVie (NYSE: ABBV) stated this week that its earnings could potentially plunge more than 20% this year. |
22,794 | 2023-02-10 00:00:00 UTC | Pharma Stock Roundup: AZN, ABBV Mixed Q4 Results, BAYRY's New CEO | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-azn-abbv-mixed-q4-results-bayrys-new-ceo | null | null | This week, AstraZeneca AZN and AbbVie ABBV announced their fourth-quarter results, with both companies beating estimates for earnings but missing on sales, like most of their counterparts. Bayer BAYRY announced the appointment of Bill Anderson as its new chief executive officer (CEO). Roche RHHBY and J&J JNJ announced ... | This week, AstraZeneca AZN and AbbVie ABBV announced their fourth-quarter results, with both companies beating estimates for earnings but missing on sales, like most of their counterparts. Recap of the Week’s Most Important Stories AstraZeneca and AbbVie’s Mixed Q4 Results: AstraZeneca’s fourth-quarter results were mix... | Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article o... | Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article o... | AbbVie too beat estimates for earnings but missed the same for sales. This week, AstraZeneca AZN and AbbVie ABBV announced their fourth-quarter results, with both companies beating estimates for earnings but missing on sales, like most of their counterparts. Recap of the Week’s Most Important Stories AstraZeneca and Ab... |
22,795 | 2023-02-10 00:00:00 UTC | Compared to Estimates, AbbVie (ABBV) Q4 Earnings: A Look at Key Metrics | ABBV | https://www.nasdaq.com/articles/compared-to-estimates-abbvie-abbv-q4-earnings%3A-a-look-at-key-metrics | null | null | For the quarter ended December 2022, AbbVie (ABBV) reported revenue of $15.12 billion, up 1.6% over the same period last year. EPS came in at $3.60, compared to $3.31 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $15.35 billion, representing a surprise of -1.52%. The company ... | For the quarter ended December 2022, AbbVie (ABBV) reported revenue of $15.12 billion, up 1.6% over the same period last year. Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue-Venclexta-United States: $269 million vers... | Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue-Venclexta-United States: $269 million versus $269.60 million estimated by five analysts on average. For the quarter ended December 2022, AbbVie (ABBV) reported revenue o... | Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue-Venclexta-United States: $269 million versus $269.60 million estimated by five analysts on average. For the quarter ended December 2022, AbbVie (ABBV) reported revenue o... | For the quarter ended December 2022, AbbVie (ABBV) reported revenue of $15.12 billion, up 1.6% over the same period last year. Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue-Venclexta-United States: $269 million vers... |
22,796 | 2023-02-10 00:00:00 UTC | SVB Leerink Upgrades AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/svb-leerink-upgrades-abbvie-abbv | null | null | On February 10, 2023, SVB Leerink upgraded their outlook for AbbVie from Underperform to Market Perform.
Analyst Price Forecast Suggests 11.73% Upside
As of February 10, 2023, the average one-year price target for AbbVie is $166.14. The forecasts range from a low of $136.35 to a high of $210.00. The average price targe... | On February 10, 2023, SVB Leerink upgraded their outlook for AbbVie from Underperform to Market Perform. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Analyst Price Forecast Suggests 11.73% Upside As of February 10... | On February 10, 2023, SVB Leerink upgraded their outlook for AbbVie from Underperform to Market Perform. Analyst Price Forecast Suggests 11.73% Upside As of February 10, 2023, the average one-year price target for AbbVie is $166.14. The projected annual revenue for AbbVie is $55,229MM, a decrease of 4.87%. | On February 10, 2023, SVB Leerink upgraded their outlook for AbbVie from Underperform to Market Perform. Analyst Price Forecast Suggests 11.73% Upside As of February 10, 2023, the average one-year price target for AbbVie is $166.14. The projected annual revenue for AbbVie is $55,229MM, a decrease of 4.87%. | The firm increased its portfolio allocation in ABBV by 27.22% over the last quarter. On February 10, 2023, SVB Leerink upgraded their outlook for AbbVie from Underperform to Market Perform. Analyst Price Forecast Suggests 11.73% Upside As of February 10, 2023, the average one-year price target for AbbVie is $166.14. |
22,797 | 2023-02-09 00:00:00 UTC | ABBV Makes Bullish Cross Above Critical Moving Average | ABBV | https://www.nasdaq.com/articles/abbv-makes-bullish-cross-above-critical-moving-average | null | null | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $149.06, changing hands as high as $153.70 per share. AbbVie Inc shares are currently trading up about 5.5% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving avera... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $149.06, changing hands as high as $153.70 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week ra... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $149.06, changing hands as high as $153.70 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week ra... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $149.06, changing hands as high as $153.70 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week ra... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $149.06, changing hands as high as $153.70 per share. AbbVie Inc shares are currently trading up about 5.5% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving avera... |
22,798 | 2023-02-09 00:00:00 UTC | AbbVie (ABBV) Q4 2022 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q4-2022-earnings-call-transcript | null | null | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q4 2022 Earnings Call
Feb 09, 2023, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning. Thank you for standing by. Welcome to the AbbVie fourth quarter 2022earnings conference call [Operator instruct... | Carrie Strom -- Senior Vice President, AbbVie, and President, Global Allergan Aesthetics Yes. AbbVie (NYSE: ABBV) Q4 2022 Earnings Call Feb 09, 2023, 9:00 a.m. Welcome to the AbbVie fourth quarter 2022earnings conference call [Operator instructions] I would now like to turn -- introduce the call to Ms. Liz Shea, senior... | Carrie Strom -- Senior Vice President, AbbVie, and President, Global Allergan Aesthetics Yes. Operator [Operator signoff] Duration: 0 minutes Call participants: Liz Shea -- Vice President, Investor Relations Rick Gonzalez -- Chairman and Chief Executive Officer Jeff Stewart -- Executive Vice President, Chief Commercial... | Carrie Strom -- Senior Vice President, AbbVie, and President, Global Allergan Aesthetics Yes. Operator [Operator signoff] Duration: 0 minutes Call participants: Liz Shea -- Vice President, Investor Relations Rick Gonzalez -- Chairman and Chief Executive Officer Jeff Stewart -- Executive Vice President, Chief Commercial... | Carrie Strom -- Senior Vice President, AbbVie, and President, Global Allergan Aesthetics Yes. Operator [Operator signoff] Duration: 0 minutes Call participants: Liz Shea -- Vice President, Investor Relations Rick Gonzalez -- Chairman and Chief Executive Officer Jeff Stewart -- Executive Vice President, Chief Commercial... |
22,799 | 2023-02-09 00:00:00 UTC | US STOCKS-Wall St dips as Treasury yields rise after auction | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-st-dips-as-treasury-yields-rise-after-auction-0 | null | null | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window
Dow down 0.73%, S&P 500 down 0.88%, Nasdaq down 1.02%
Weak demand for $21 bln sale of 30-year Treasury bonds
PepsiCo gains on quarterly profit, sales beat
Disney beats earnings estimates but ends down
Salesforce r... | PepsiCo Inc PEP.O rose 0.95% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 2.82% after beating fourth-quarter profit expectations. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Dow down 0.73%, S... | PepsiCo Inc PEP.O rose 0.95% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 2.82% after beating fourth-quarter profit expectations. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Dow down 0.73%, S... | PepsiCo Inc PEP.O rose 0.95% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 2.82% after beating fourth-quarter profit expectations. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Dow down 0.73%, S... | PepsiCo Inc PEP.O rose 0.95% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 2.82% after beating fourth-quarter profit expectations. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Dow down 0.73%, S... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.